RESTRICTION OF APOPTOSIS IN MATURE NEURONS BY MULTIPLE REDUNDANT BRAKES by Annis, Ryan
 
RESTRICTION OF APOPTOSIS IN MATURE NEURONS BY MULTIPLE REDUNDANT 
BRAKES 
 
Ryan Patrick Annis 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy in the Curriculum of 
Neurobiology. 
 
Chapel Hill 
2016 
 
 
             Approved by: 
 
             Mohanish Deshmukh 
 
             Benjamin Philpot 
 
             Jay Brenman 
 
                       Kathleen Caron 
 
             Scott Hammond 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©2016 
Ryan Patrick Annis 
ALL RIGHTS RESERVED 
 
 
iii 
 
 
ABSTRACT 
 
Ryan Patrick Annis: Restriction of Apoptosis in Mature Neurons by Multiple Redundant 
Brakes 
(Under the Direction of Mohanish Deshmukh) 
 
 Apoptotic cell death is a key part of normal nervous system development, as a 
process that allows for the controlled removal of developing neurons that fail to properly 
integrate into the nervous system. However, once the nervous system is established, 
the production of new neurons is halted in most areas of the nervous system, meaning 
that neurons remaining after the establishment of the nervous system must last for the 
lifetime of the organism. Aberrant or accidental activation of the apoptotic pathway 
would be deleterious for this long-term neuronal survival, and neurons have been found 
to restrict the apoptotic pathway as they mature. However, while the resistance of 
mature neurons to apoptosis is well documented, the precise molecular mechanisms 
underlying this resistance have remained unclear.  
 Recent findings from our lab found that one way neurons can restrict Bax 
activation is by upregulating the members of the miR-29 family of microRNAs, which 
can inhibit Bax activation by blocking the upregulation of multiple redundant members of 
the BH3-only family of proteins. While overexpression of miR-29 has been found to be 
sufficient to render young neurons resistant to apoptosis, it was unclear whether the 
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miR-29 family of miRNAs was the only brake restricting Bax activation in mature 
neurons, or if other brakes on Bax activation exist.   
 The work presented in this dissertation addresses this question by examining the 
status of the apoptotic pathway in neurons from mice in which all three members of the 
miR-29 family have been deleted. I found that in neurons lacking miR-29 expression, 
the apoptotic pathway remains restricted. I identified miR-24 as a microRNA that is also 
upregulated with neuronal maturation, which can act redundantly with miR-29 by 
repressing a similar repertoire or BH3-only domain genes. Additonally, I found that 
mature neurons are more resistant to Bax activation induced by direct injection of BH3-
only peptides, and that mature neurons may also block apoptosis by restricting the 
phosphorylation and activation of the pro-apoptotic transcription factor c-jun. My findings 
also suggest that mature neurons are able to restrict the apoptotic pathway in the soma 
while maintaining a permissive environment in their axons. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Apoptosis: A Brief History 
 Death is an unavoidable and important aspect of life, but death is something that 
all organisms, including humans, instinctually avoid in most cases. However, in most 
eukaryotes, decisions about life and death are constantly taking place at a cellular level, 
and are crucially important for both the development and health of complex organisms 
like mammals. The work of many researchers throughout the years has uncovered a 
process of voluntary, genetically programmed self-destruction that takes place in 
mammalian cells, called apoptosis.  
 The term apoptosis was first coined by the researchers Kerr, Wyllie, and Curry in 
1972. They described a process of “controlled cell deletion” that opposed the process of 
mitosis, or cell division, in mammalian cells for the purposes of regulating the size of cell 
populations (Kerr, Wyllie et al. 1972). Early observations in developing chick embryos 
found that the same populations of cells would undergo cell death at the same time-
point during embryonic development, suggesting that cell death might be a normal, 
voluntary, and perhaps genetically programmed part of development (Hinchliffe and 
Johnson, 1980).  
 The molecular mechanisms underlying apoptosis remained a mystery until 1986, 
when Robert Horvitz of MIT, working in the nematode worm caenorhabditis elegans, (C. 
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elegans). C. elegans was an ideal model system to explore programmed cell death, 
because every worm consists of exactly 1090 cells, of which 131 are lost during 
development in a highly reproducible fashion (Sulston and Horvitz 1977). Using a 
forward genetic screen in these worms, Horvitz identified the first “death genes”, called 
ced-3 and ced-4. Horvitz showed that functional ced-3 and ced-4 genes were necessary 
for the execution of the cell death program (Ellis and Horvitz 1986). In 1988, 
researchers identified the B-Cell Lymphoma 2 (BCL-2) oncogene, which promoted 
survival in mammalian B-Cells (Vaux, Cory et al. 1988). A gene with similar function, 
ced-9, was discovered in C. elegans in 1992 (Hengartner, Ellis et al. 1992), and later 
that same year, it was discovered that expression of human BCL-2 in C.elegans was 
able to inhibit cell death, providing strong evidence that BCL-2 performed an 
evolutionarily conserved function of opposing cell death in both worm and mammalian 
cells (Vaux, Weissman et al. 1992). Indeed, later work would find that BCL-2 and ced-9 
are actually the same evolutionarily conserved gene (Hengartner and Horvitz 1994).  
 The evidence that an evolutionarily conserved programmed cell death pathway 
existed between worms and humans set researchers to searching for other homologues 
conserved between the two organisms. In 1993, a mammalian homologue of ced-3 was 
discovered, which would become the first member of the family of proteins known as 
cysteine aspartic proteases, or caspases, now known to be essential for the execution 
of mammalian apoptosis (Yuan, Shaham et al. 1993). In 1997, a mammalian 
homologue of ced-4 was discovered, named Apoptosis Activating Factor 1, or Apaf-1 
(Zou, Henzel et al. 1997) In 1998, EGL-1, a protein which in C. elegans opposes the 
action of ced-9 to promote the execution of apoptosis, was identified (Conradt and 
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Horvitz 1998). In 1996, the central role played by the mitochondria in apoptosis was 
established by the discovery that translocation of the electron transport chain protein 
cytochrome c (cyt c) was essential for the activation of the apoptotic program. (Liu, Kim 
et al. 1996). 
 The connection between cyt c release from the mitochondria and BCL-2 was 
established by the finding that BCL-2 overexpression is able to inhibit apoptosis by 
preventing cyt c release (Kluck, Bossy et al. 1997). It was subsequently discovered that 
cyt c release is governed by complex interactions between multiple members of what 
came to be known as the BCL-2 family of proteins. Named after the founding member of 
the family (described above), the BCL-2 family is now known to consist of subgroups of 
multiple anti- and pro-apoptotic members that serve redundant functions(Danial and 
Korsmeyer 2004).  The first pro-apoptotic member of the family, Bax, was discovered in 
1993 based on its interaction with BCL-2 (Oltvai, Milliman et al. 1993). It was 
subsequently found that Bax and BCL-2 have opposing functions in the regulation of 
apoptosis, with Bax promoting the release of cyt c from the mitochondria and BCL-2 
acting to inhibit this process (Jurgensmeier, Xie et al. 1998; Rosse, Olivier et al. 1998).  
 
The BCL-2 Family 
 The BCL-2 family is now divided into three groups defined by function and by 
homology of BH1-4 domains within the family (Figure 1.1). The first group, the anti-
apoptotic BCL-2 members, consists of BCL2, BCL-XL, MCL-1, A1, and BCL-W (Boise, 
Gonzalez-Garcia et al. 1993; Kozopas, Yang et al. 1993; Choi, Boise et al. 1995). 
4 
 
These members are characterized by conservation of BH1-4 domains and act to inhibit 
cell death.  
 The second group, known as multidomain proapoptotic BCL-2 family proteins, 
consists of Bax and Bak. These members exist as inactive monomers in the cytosol, 
and undergo conformational changes that result in their translocation to the 
mitochondria to promote the release of cyt c and subsequently apoptosis. Bax and Bak 
exhibit conserved expression of BH1-3 domains and serve as key gatekeepers on the 
apoptotic pathway, as loss of Bax and Bak expression is sufficient to render cells 
resistant to all known intrinsic apoptotic stimuli (Lindsten, Ross et al. 2000; Wei, Zong et 
al. 2001).  
 The third and largest group of BCL-2 family proteins consists of the pro-apoptotic 
BH3-only domain proteins, which bear strong structural homology with the pro-death c. 
elegans protein EGL-1(Conradt and Horvitz 1998). This family promotes Bax activation 
and apoptosis by acting upstream of the mitochondria, and is regulated at both the 
transcriptional level and by post-translational modification (Lomonosova and 
Chinnadurai 2008). BH3-only domain proteins promote the activation of Bax and 
apoptosis, but there is some controversy over the precise mechanism by which this is 
accomplished. Two non-mutually exclusive models have been proposed, called the 
direct and indirect activation models.  
 In the direct activation model, “activator” BH3 proteins, a group thought to be 
comprised of Bim, Puma, and Bid, are held in check by binding to the anti-apoptotic 
proteins BCL-2, BCL-xl, BCL-W and MCL-1. In this model, the direct binding of 
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activators to Bax itself is essential for apoptosis to proceed. In the indirect activation 
model, Bax and Bak are constitutively active and held in check by binding to the anti-
apoptotic BCL-2 family proteins. In this model, the BH3-only domain proteins promote 
apoptosis by liberating active Bax from BCL-2 family proteins and permitting the 
translocation of Bax to the mitochondria, where it promotes apoptosis (Shamas-Din, 
Brahmbhatt et al. 2011). These models are not mutually exclusive and requirements for 
the induction of apoptosis may vary based on the endogenous expression levels of the 
various BCL-2 family genes in different cell types.  
Caspases 
 The ultimate execution of the apoptotic pathway in mammalian cells is carried out 
by caspases (Figure 1.2). Caspases are a family of cysteine proteases that can be 
divided into two functional groups: effectors and initiators. Effector caspases, a group 
comprised of Caspases-3, -6, and -7, exist as inactive zymogens in the cytosol of 
mammalian cells, and remain inactive until cleaved by initiator caspases, a group 
comprised of Caspase-2, -9, -8, and -10. Caspase-8 and-10 act in the extrinsic pathway 
of apoptosis, and contain a Death Effector Domain (DED), while Caspase-2 and -9 act 
in the intrinsic apoptosis pathway, and contain Caspase Activation Recruitment 
Domains (CARDs) (Riedl and Shi 2004). 
 The activation of the initiator caspase, Caspase 9, is governed by a large protein 
complex called the apoptosome. The apoptosome is formed when cyt c, after its release 
from the mitochondria, binds to the CED-4 homologue Apaf-1, along with dATP, to form 
a large protein complex known as the apoptosome, which mediates the catalytic 
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cleavage and activation of Caspase-9. Caspase-9 then cleaves and activates 
executioner caspases such as Caspase-3/7, which cleave a variety of downstream 
substrates, resulting in the final death of the cell (Li, Nijhawan et al. 1997; Zou, Henzel 
et al. 1997). 
  
1.2 Apoptosis in Development and Disease 
 Defects in the apoptotic program are associated with a wide range of disorders, 
most notably cancer (Hanahan and Weinberg 2000; Hanahan and Weinberg 2011). 
Indeed, the anti-apoptotic BCL-2 gene was discovered based on its overexpression in 
follicular lymphoma (Vaux, Cory et al. 1988). Since this discovery, abundant evidence 
has accumulated that many cancer types exhibit mutations or changes in gene 
expression that interfere with the proper function of the apoptotic pathway. For example, 
the well-known tumor suppressor P53 is mutated in 50% of human cancers, and is 
known to induce apoptosis through transcriptional upregulation of the BH3-only domain 
proteins Puma and Noxa (Oda, Ohki et al. 2000; Nakano and Vousden 2001). Mutations 
in P53 that interfere with its function prevent the induction of the cell death program and 
allow cancer cells to continue to survive and proliferate.  
 The apoptotic pathway also plays a key role in the development of many 
organisms. For example, over the course of normal limb development, many organisms 
possess interdigital webbing that is normally lost through apoptosis. In mice where 
genes in the apoptotic pathway are mutated or removed, this webbing persists long 
after it would normally have been lost (Lindsten, Ross et al. 2000). The main subject of 
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this study, however, will focus on neurons, a population of cells unique in many ways 
from others in the body, not least of which is their ability to precisely spatially and 
temporally regulate the apoptotic pathway.  
 
1.3 Apoptosis in Neurons 
 Neurons are the building blocks and key functional units of the nervous system. 
They are unique among cells in their ability to form connections, called synapses, with 
muscles, glands, and other neurons, through which they transmit signals via the release 
of chemicals known as neurotransmitters. The development of the nervous system is 
governed by a variety of complex and overlapping processes. Neurons differentiate 
from neuronal precursor cells, and must migrate to the appropriate location and form 
connections with the correct targets. These processes often occur simultaneously at the 
cellular level during development (Figure 1.3). Regulation of these processes in various 
populations of neurons is the subject of intensive ongoing research that is beyond the 
scope of this dissertation. Instead, we will focus on the apoptotic pathway in neurons, 
which is employed in the developing nervous system to remove neurons that fail to 
integrate into the nervous system properly as a result of defects in differentiation, 
migration, or target innervation. 
 A noteworthy characteristic of neurons compared to other populations of cells is 
that neurons are terminally differentiated cells that, with few exceptions, do not undergo 
division in the mature nervous system. Therefore, once a neuron is born and integrated 
into the nervous system, that neuron remains there for the lifetime of the organism, and 
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if lost, cannot easily be replaced. One might expect, given the requirement that neurons 
survive for the lifetime of an organism, that these cells would not possess an active 
apoptotic pathway. On the contrary, however, apoptosis plays a key role in nervous 
system development and function. Indeed, mice deficient for key proteins in the 
apoptotic pathway exhibit craniofacial defects and early embryonic lethality stemming 
from overproliferation of neuronal precursors (Figure 1.4). 
 The observation that neurons undergo cell death as a part of normal 
development was first made by Dr. Erich Kallius in 1926 (Ernst 1926). Many of the key 
early observations in the neuronal cell death field, however, were made by Dr. Rita Levi 
Montalcini and Dr. Viktor Hamburger beginning in 1949. In 1960, Dr. Montalcini injected 
neonatal mice with a neutralizing antibody to the newly-discovered protein Nerve 
Growth Factor, or NGF, and observed almost total degeneration in the mouse 
sympathetic nervous system (Levi-Montalcini and Booker 1960). This observation 
represented both a key discovery in the role of cell death in neuronal development, as 
well as the birth of the sympathetic neuron model of neuronal apoptosis, which has 
proven to be one of the most informative models of neuronal cell death to date. 
 Sympathetic neurons are a population of neurons in the peripheral nervous 
system (PNS) that are perhaps the best understood model of neuronal apoptosis. 
Mouse sympathetic neurons undergo extensive cell death as a part of normal 
development in the first week of postnatal life in mice (Wright, Cunningham et al. 1983). 
During this time period, these neurons are acutely dependent on Nerve Growth Factor, 
or NGF, for their survival (Levi-Montalcini and Booker 1960). NGF is secreted in limiting 
amounts from target organs, glands, and muscles, and binds the TRKA receptor in 
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sympathetic neuron terminals to promote cell survival. Neurons that properly innervate 
their targets and obtain NGF survive and mature, while neurons that fail to innervate 
their targets are eliminated by apoptosis during the first postnatal week (Glebova and 
Ginty 2005). 
 Sympathetic neurons are an attractive model for the study of apoptosis because 
they can be isolated from neonatal mice and maintained in culture by adding exogenous 
NGF to the cell culture media. Switching cells to NGF-free media results in neuronal 
death within 48-72 hours, and early studies noted that this death features the hallmarks 
of apoptosis, including chromatin condensation, DNA fragmentation, declines in RNA 
and protein synthesis, and membrane disruption. This death was also found to depend 
on protein synthesis, as pharmacological inhibition of protein synthesis is able to 
significantly delay cell death. This requirement for active protein synthesis highlights the 
voluntary “self-destructive” nature of apoptosis in neurons (Martin, Schmidt et al. 1988; 
Martin, Ito et al. 1992; Deckwerth and Johnson 1993; Edwards and Tolkovsky 1994).  
 NGF deprivation has been found to induce the intrinsic apoptosis pathway in 
sympathetic neurons (Figure 1.5). In this pathway, an apoptotic stimulus such as NGF 
deprivation leads to both the upregulation of the transcription factor c-jun and its 
phosphorylation by JNK family kinases. Inhibition of c-jun with neutralizing antibodies or 
expression of a dominant-negative c-jun mutant inhibits apoptosis (Estus, Zaks et al. 
1994; Ham, Babij et al. 1995). Phosphorylated c-jun translocates to the nucleus, and 
promotes the transcriptional induction of multiple pro-apoptotic BH3-only genes. The 
balance between these pro-apoptotic BH3-only genes and anti-apoptotic the BCL2 
family genes BCL2, BCL-XL and MCL-1 is thought to govern Bax activation. Indeed, 
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overexpression of BCL2 inhibits cell death and cyt c release in NGF-deprived 
sympathetic neurons, and neurons from BCL2- deficient animals die faster than their 
wild-type counterparts (Garcia, Martinou et al. 1992; Greenlund, Korsmeyer et al. 1995). 
Similarly, overexpression of BCL-xL and MCL-1 have been found to promote neuronal 
resistance to apoptosis (Gonzalez-Garcia, Garcia et al. 1995; Arbour, Vanderluit et al. 
2008).  
 Since the BH3-only proteins govern the activation of Bax and the release of cyt c 
from the mitochondria, their roles in neurons have been the subject of considerable 
study. It is now known that NGF-deprivation in sympathetic neurons leads to the 
transcriptional upregulation of four BH3-only proteins: Bim, Puma, BMF, and HRK 
(Kristiansen, Menghi et al. 2011). Overexpression of these genes is sufficient to induce 
or accelerate cell death in neurons; however, knockout of any of these genes on their 
own is at best only partially protective from apoptosis in neurons, suggesting that these 
proteins may have overlapping functions (Whitfield, Neame et al. 2001; Wyttenbach and 
Tolkovsky 2006; Coultas, Terzano et al. 2007; Pfeiffer, Anilkumar et al. 2014). Indeed, it 
has been found that knockout of Bim and Puma together provides significantly 
enhanced protection from apoptosis in the cerebellar granule neuron model of apoptosis 
compared to individual knockout of either gene alone, and additional deletion of Bid to 
generate Bim/Puma/Bid knockout neurons phenocopies knockout of Bax/Bak in the 
cerebellum (Ren, Tu et al. 2010). 
 The regulation of the transcriptional induction of BH3-only genes is the subject of 
ongoing study. Early experiments described above established the importance of the 
transcription factor c-jun in neuronal apoptosis. C-jun has been found to bind to the 
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promoter of the BH3-only gene Bim and participate in its transcriptional upregulation 
(Whitfield, Neame et al. 2001). It has subsequently been discovered that the activation 
of Bim in NGF-deprived sympathetic neurons requires the participation of a number of 
other factors in addition to c-jun, including the Myb and Forkhead Box (FOXO) 
transcription factors, which bind to the Bim promoter and first intron (Gilley, Coffer et al. 
2003; Biswas, Shi et al. 2007). More recent studies discovered binding sites for the 
transcription factor NF-Y in the Bim promoter, and found that NF-Y forms a complex 
with FOXO3A and CBP/P300 proteins to promote increased Bim transcription. It has 
been hypothesized that CBP/P300 may integrate the contributions of various pro-
survival and death signals at the Bim promoter to regulate Bim induction (Hughes, 
Kristiansen et al. 2011). 
 The various transcription factors that control Bim induction in sympathetic 
neurons undergoing apoptosis are regulated by several different pathways. C-jun 
phosphorylation is known to be regulated by the MLK/JNK pathway. During apoptosis, 
MLKs become active and phosphorylate JNKs, which in turn phosphorylate c-jun. 
Phospho-c-jun translocates to the nucleus, where it acts as a pro-death transcription 
factor (Davis 2000). Activity of the FOXO transcription factors is governed by their 
phosphorylation. It has been found that the AKT pathway, which is stimulated by NGF, 
phosphorylates FOXO transcription factors, resulting in their sequestration in the 
cytoplasm by 14-3-3 proteins. In response to NGF deprivation, the activity of the PI3K-
AKT pathway declines, leading to the dephosphorylation of FOXOs, which then 
translocate from the cytoplasm to the nucleus to stimulate pro-apoptotic gene 
expression (Gilley, Coffer et al. 2003; Zareen, Biswas et al. 2013). Another pro-survival 
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pathway stimulated by NGF, the Raf-MEK-ERK pathway, is thought to promote survival 
by phosphorylating and activating the transcription factor RSK, which promotes survival 
by phosphorylating and activating the pro-survival factor CREB (Riccio, Ahn et al. 
1999). More recently, ERK has been found to directly repress Bim gene induction by 
direct binding to the 3’UTR of Bim RNA, although to date the mechanism remains 
unclear (Hughes, Gilley et al. 2011). 
 Other pro-death transcription factors, such as the Myb proteins, are thought to be 
regulated by cell cycle induction. It has been found that neurons stimulated to undergo 
apoptosis upregulate cell-cycle genes like Cyclin D1 and reenter the cell cycle, and that 
pharmacological inhibitors of cell cycle progression, such as the CDK inhibitors 
Roscovitine and Flavopiridol, are potent inhibitors of neuronal apoptosis (Freeman, 
Estus et al. 1994; Liu and Greene 2001). 
 
1.4 Apoptosis in Nervous System Pathologies  
 The discovery of a pathway mediating programmed neuronal cell death spurred 
considerable interest in exploring its involvement in neuropathological conditions. The 
mechanism by which neurons die in these disorders is of particular interest to this 
dissertation because many of these conditions afflict older individuals, whose neurons 
would be resistant to apoptosis under normal conditions. Unfortunately, despite many 
years of intensive study, the evidence for the contribution of apoptosis is mixed, and 
varies considerably between different disorders. 
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Alzheimer’s Disease 
 Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder 
characterized by memory problems, dementia, and progressive neuronal death, which 
was estimated to afflict 5.1 million Americans as of 2013. The chief risk factor for AD 
has been found to be age, and the number of patients is expected to grow rapidly as the 
population ages, according to the US centers for Disease Control.  
 The pathological hallmarks of AD are neurofibrillary tangles composed of the 
cytoskeletal associated protein Tau and extracellular plaques composed of the protein 
Amyloid-β (Aβ), as well as progressive loss of neurons and synapses (Serrano-Pozo, 
Frosch et al. 2011). The extent to which apoptosis contributes to the loss of neurons 
and synapses during AD is controversial. Some studies have reported widespread 
expression of apoptotic markers, while others have reported small or absent changes in 
expression of apoptotic markers between diseased brains and age-matched controls 
(Su, Anderson et al. 1994; Troncoso, Sukhov et al. 1996; Selznick, Holtzman et al. 
1999; Su, Zhao et al. 2001; Woodhouse, Dickson et al. 2006). Characterizing cell death 
in post-mortem samples from degenerating human brains is challenging, mainly 
because neurons that die are cleared by microglial phagocytosis (Takahashi, Rochford 
et al. 2005). Since cell death in humans suffering from AD occurs gradually over the 
course of many years, at any given time, only a small number of neurons would be 
caught in the act of dying during any given “snap shot”, and any dead neurons would be 
quickly removed and thus impossible to detect. 
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 Interestingly, while the evidence that apoptosis contributes to neuron loss in AD 
patient brains is controversial, substantial evidence exists that Beta-Amyloid (Aβ), one 
of the proteins that make up the hallmark lesions found in the AD brain, has a pro-
apoptotic effect on neurons. Incubation of cortical neurons with purified Aβ has been 
found to induce robust cell death (Morishima, Gotoh et al. 2001). Aβ-induced death has 
been found to be Bax dependent and dying neurons were found to exhibit cleaved 
caspase 3, but pharmacological inhibition or genetic knockout of caspase 3 failed to 
prevent cell death of Aβ treated telencephalic neurons. This suggests that arrest of 
apoptosis after the point of cyt c release is not able to prevent neurons from dying in 
reponse to Aβ, but inhibition prior to the release of cyt c can promote survival (Selznick, 
Zheng et al. 2000). More recently, it has been found that exposure to Aβ causes 
increases in the levels of Bim and active Bax, while decreasing the levels of BCL-2, in 
organotypic hippocampal slice cultures or in the hippocampi of 2-3 month old mice 
injected with Aβ intrahippocampally (Kudo, Lee et al. 2012). Aβ was subsequently found 
to upregulate Bim via a Foxo3a-dependent mechanism in cultured cortical neurons 
(Sanphui and Biswas 2013).  
 While the evidence for Aβ toxicity is substantial, the role that Tau, plays in AD 
pathology is less clear. Tau has been well established to exist in a hyper-
phosphorylated state in the brains of AD patients, but how hyper-phosphorylated Tau 
contributes to the progression of the disease, and whether the presence of hyper-
phosphorylated Tau reflects a cause or a consequence of AD is still unclear. Tau is a 
protein that typically associates with microtubules and promotes their polymerization 
and assembly. Under pathological conditions, Tau becomes hyperphosphorylated and 
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no longer associates with microtubules, and accumulates in the cytosol in the form of 
neurofibrillary tangles (NFTs).  
 It is thought that a combination of loss of endogenous Tau function as well as 
pathological gain-of-function in hyperphosphorylated Tau contributes to neuronal 
dysfunction in AD (Ballatore, Lee et al. 2007). For example, in mouse models of 
tauopathy, neurons exhibit defects in axonal transport that can be rescued by treatment 
with microtubule stabilizing drugs (Zhang, Maiti et al. 2005). Interestingly, 
hyperphosphorylation of Tau has been found in several studies to be neuroprotective 
and to inhibit apoptosis, suggesting that the toxic effects of Tau may be due to indirect 
effects or toxic intermediates rather than a direct toxic effect of the hyperphosphorylated 
Tau present in NFTs (Li, Wang et al. 2007; Liu, Liao et al. 2010; Duan, Chai et al. 
2013). A recent finding also found that Tau expression is important for the clearance of 
Aβ plaques in cultured hippocampal neurons and mouse brain, suggesting that there 
may be crosstalk between Tau and Aβ during AD pathogenesis (Lonskaya, Hebron et 
al. 2014)  
Parkinson’s Disease 
 Parkinson’s Disease (PD) is the second most common neurodegenerative 
disease in the US, afflicting some 1 million Americans. It is characterized by progressive 
motor deficits including tremor, slowed movement, muscle rigidity, impaired posture, 
and loss of automatic movements. It also features nonmotor symptoms, including sleep 
disturbance, sensory abnormalities, and cognitive decline.  
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 The reason for the classical motor symptoms of PD is the progressive loss of 
dompaminergic neurons in the Substantia Nigra (SNc) region of the brain. PD is also 
associated with the presence of insoluble protein aggregates known as Lewy Bodies, 
which are made up of aggregated α-synuclein protein, among other proteins. In addition 
to the Nigro-Striatal pathway, other brain nuclei have been found to degenerate with 
Lewy Body pathology. The degeneration of these nuclei is believed to contribute to 
many of the non-motor symptoms of PD (Jellinger 2012; Dexter and Jenner 2013). 
 Similar to AD, the contribution of apoptosis to the progression of PD is 
controversial. Evidence from animal and cell culture models of PD suggested that 
apoptosis played a prominent role in PD. PD has been modeled in vitro and in mouse 
models using inhibitors of mitochondrial complex I, namely the toxins MPP+, MPTP, and 
rotenone. These toxins cause energy failure and oxidative stress in cells, and their 
injection into mice causes a Parkinson’s-like pathology (Dauer and Przedborski 2003). 
Injection of these compounds into mice was found to cause increased apoptosis in the 
Substantia Nigra (SNc) region of the brain (Tatton and Kish 1997; Viswanath, Wu et al. 
2001). 
 MPTP administration was shown to cause cell death in the brains of mice in a 
JNK dependent manner (Xia, Harding et al. 2001; Saporito, Hudkins et al. 2002). 
Further evidence for the involvement of apoptosis in PD pathology came from the 
finding that active Bax is present in the brain tissue of MPTP-treated mice, 6OHDA 
lesioned mice (an alternative model of PD) and the brains of human PD patients 
(Hassouna, Wickert et al. 1996; Tatton 2000; Hartmann, Michel et al. 2001; Vila, 
Jackson-Lewis et al. 2001; Perier, Bove et al. 2012). Ablation or inhibition of Bax was 
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found to be protective in mouse models of PD (Vila, Jackson-Lewis et al. 2001; Perier, 
Bove et al. 2007). Overexpression of BCL-2 was also found to be protective in both in 
vitro and in vivo models of PD, although the degree of protection varies depending on 
the dosage regimen of MPTP (Offen, Beart et al. 1998; Yang, Matthews et al. 1998; Vila 
and Przedborski 2003). 
 The abundance of evidence for the involvement of apoptosis in preclinical 
models of PD led to the initiation of clinical trials examining whether a drug that inhibits 
neuronal apoptosis could improve patient outcomes in PD. The drug tested, CEP-1347, 
is a Mixed Lineage Kinase Inhibitor, which inhibits apoptosis at an early point in the 
pathway by preventing MLK-JNK activation. CEP-1347 was found to inhibit neuronal 
apoptosis in multiple models of developmental and pathological cell death (Wang, Ma et 
al. 2004). Unfortunately, the CEP-1347 trial was stopped early when an interim analysis 
of the data determined that it would be “futile” to continue the trial due to the drug’s lack 
of efficacy (Parkinson Study Group PRECEPT Investigators, 2007). The reason for the 
failure of promising preclinical data to translate to the clinic is unclear, but may reflect 
inadequacy of the current animal and cellular models to accurately depict human 
disease, or the presence of other “back-up” cell death pathways, such as necrotic or 
autophagic cell death, that are engaged when apoptosis is inhibited (Venderova and 
Park 2012). 
Amyotrophic Lateral Sclerosis 
 Amyotrophic Lateral Sclerosis, or ALS, also known as Lou Gehrig’s Disease, is a 
degenerative disorder affecting the motor neurons of the spinal cord. Its symptoms 
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include muscle weakness, atrophy, and spasticity. Approximately 5-10% of ALS cases 
are familial, and have been found to be caused by specific mutations, most notably a 
toxic gain-of-function mutation in the Superoxide Dismutase 1 (SOD1) gene. Familial 
ALS can also be caused by hexanucleotide repeat expansion of the C9ORF72 gene, 
and mutations in the RNA processing gene TARDBP.  
 The pathology of ALS involves progressive loss of motor neurons in the anterior 
horns of the spinal cord and in the motor nuclei of the brainstem. Denervation of 
muscles after motor neuron death leads to muscle atrophy. Most ALS patients die within 
2-3 years of the onset of symptoms, usually of respiratory muscle paralysis. 
 The role of apoptosis in ALS was recently examined by crossing mice bearing 
the SODG93A mutation, which is known to lead to familial ALS in humans. Apoptosis was 
inhibited in these animals by crossing them with a mouse line lacking CNS expression 
of Bax and Bak, two genes which are required for activation of the mitochondrial 
apoptotic pathway.  Double deletion of Bax and Bak was found to delay neuronal loss, 
symptom onset, and preserve neuronal function in these mice, as well as increasing 
lifespan by 21%. These findings suggest that apoptosis plays a role in the progression 
of ALS, but also highlight that apoptosis alone is not responsible for the observed 
symptoms in this disease (Reyes, Fisher et al. 2010). Consistent with this finding, 
inhibition of apoptosis with caspase inhibitors or BCL-2 overexpression also delays, but 
does not prevent, the onset and progression of ALS symptoms (Kostic, Jackson-Lewis 
et al. 1997; Azzouz, Hottinger et al. 2000).  
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 As the research summarized above demonstrates, while there is evidence that 
apoptosis contributes to the progression of some neurodegenerative diseases, it has 
been difficult to translate even the most promising preclinical data into successful 
treatments in humans. While improved animal models of neurodegeneration would no 
doubt aid in this process, it appears at this point that inhibition of apoptosis will not 
serve as a “magic bullet” in the treatment of neurodegenerative disorders.  
 
1.5: Introduction to microRNAs 
 MicroRNAs (miRNAs) are small (~22 nucleotide) single-stranded RNAs that act 
as regulators of gene expression. miRNAs are typically transcribed from genomic DNA 
by RNA Polymerase II (Pol II) to produce a primary transcript, or pri-miRNA. These pri-
miRNAs include stem-loop structures that will eventually be processed into mature 
miRNAs, as well as varying amounts of surrounding RNA. In the next step of miRNA 
biogenesis, these stem-loop structures are cleaved from the surrounding RNA by the 
microprocessor complex, which includes the proteins DGCR8 and Drosha. The product 
of this cleavage event is a ~65 nucleotide hairpin structure known as a pre-miRNA. 
Following this cleavage, pre-miRNAs are exported from the nucleus to the cytoplasm 
via the nuclear pore complex. The most important protein for this export process is the 
nuclear transport receptor Exportin-5 (Ha and Kim 2014).  
 Following nuclear export, the pre-miRNA hairpin structure is further processed in 
the cytoplasm near the terminal loop, resulting in a small RNA duplex consisting of two 
strands of ~22 nucleotides in length. This duplex is loaded into a protein complex, the 
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RNA-Induced Silencing Complex (RISC), at which point one strand, the passenger 
strand, is removed by cleavage or unwinding. The strand remaining in the RISC, known 
as the guide strand, is able to participate in RNA silencing at this point, while the 
removed passenger strand is typically degraded rapidly. Argonaute proteins, especially 
Argonaute 2 (Ago2), are critical for miRNA silencing activity (Huntziner et al., 2011). 
miRNAs bind primarily to the 3’ untranslated regions (3’UTRs) of target mRNAs in a 
sequence-dependent manner and mediate their silencing through translational inhibition 
or RNA degradation (Ha and Kim 2014). A schematic of this process is shown in Figure 
1.6.  Target selection is mediated by a short sequence within each miRNA known as the 
seed sequence, with miRNAs within families (e.g. miR-29a, b, and c) sharing conserved 
seed sequences. 
 
1.6 MicroRNAs in Nervous System Development and Disease 
 Since their discovery in the 1990s, miRNAs have been implicated in a wide 
variety of biological processes and pathologies. Indeed, it has been estimated that more 
than 60% of genes in the human genome are targeted by at least one miRNA. The 
importance of miRNAs for proper mammalian development is strongly supported by 
data from mouse knockout studies. Germline knockout of Drosha or Dicer leads to 
embryonic lethality in mice by embryonic day 7.5 (Park, Choi et al. 2010),  while 
knockout of DGCR8 leads to arrest early in embryonic development, with DGCR8-
deficient stem cells exhibit defective proliferation and differentiation (Wang, Medvid et 
al. 2007). 
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 miRNAs have also been found to play crucial roles in neuronal development and 
disease. For example, deletion of Dicer using the cerebral cortex-specific Emx1-Cre line 
results in a range of defects, including decreased survival and differentiation (De Pietri 
Tonelli, Pulvers et al. 2008; Kawase-Koga, Otaegi et al. 2009). Deletion of Dicer using 
the CAMKII promoter, which is specific to postmitotic neurons of the cortex and 
hippocampus, results in decreased cortical size, enhanced neuronal cell death, defects 
in axon pathfinding, and impaired dendritic branching (Davis, Cuellar et al. 2008). 
Certain aspects of these Dicer-deletion phenotypes have been attributed to specific 
miRNAs. miRNAs, including miR-124, miR-9, and Let-7 have been found to promote 
neuronal differentiation, neurite outgrowth, and synaptogenesis (Bian and Sun 2011; 
McNeill and Van Vactor 2012). miR-128 was found to be highly expressed in adult 
neurons and to regulate neuronal excitability and mouse motor behavior. Knockdown of 
miR-128 in the brain was found to lead to neuronal hyperexcitability and fatal epilepsy, 
while overexpression of miR-128 was found to suppress motor activity and alleviate 
motor abnormalities associated with Parkinson’s-like disorders in mice (Tan, Plotkin et 
al. 2013). 
 microRNAs have also been implicated in various neurodegenerative disease 
states and in cases of acute neuronal injury, such as stroke. Selective ablation of Dicer 
in adult forebrain neurons was found to result in cellular shrinkage, neurodegeneration, 
and abnormal phosphorylation of the cytoskeletal protein Tau, which is a hallmark of 
Alzheimer’s Disease (Hébert, Papadopoulou et al. 2010).  
 Screens performed in age-matched human patient samples as well as mouse 
models of neurodegenerative disease  have yielded a number of miRNA candidates that 
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may play a role in the etiology of neurodegenerative disorders (Table 1.1). While the 
candidates summarized in Table 1.1 were selected for analysis based primarily on their 
ability to target disease-specific genes, such as α-synuclein in Parkinson’s disease or β-
Site APP-Cleaving Enzyme 1 (BACE1) in Alzheimer’s Disease. However, disruption of 
other miRNA functions, such as the ability of miR-29 to regulate apoptosis, could also 
play an important role in the progression or onset of neurodegenerative disease, and 
merits further investigation (Kole, Swahari et al. 2011). The effects of these non-
disease-specific functions of miRNAs will likely become clearer as more miRNA-specific 
knockout organisms are generated. For example, in Drosophila, knockout of miR-34 has 
been shown to lead to late-onset brain degeneration, decreased lifespan, and a gene-
expression profile consistent with accelerated aging. Conversely, overexpression of 
miR-34 extended lifespan and mitigated neurodegeneration induced by overexpression 
of a pathogenic (poly-glutamine) ataxin-3 protein (Liu, Landreh et al. 2012).  
 
1.7 Increasing Resistance to Apoptosis with Neuronal Maturation 
 Early in the development of the mammalian nervous system, neurons are acutely 
sensitive to apoptosis. As referenced above, when Dr. Rita Levi-Montalcini injected 
neonatal mice with an antigen that neutralized the activity of nerve growth factor in vivo, 
she observed widespread cell death in the sympathetic ganglia, with more than 99% 
neuron loss in most cases ((Levi-Montalcini and Booker 1960), Figure 1.7). However, 
Montalcini and colleagues later discovered that in adult mice treated with the same 
neutralizing antibody, a significant proportion of sympathetic neurons were able to 
survive. Further experiments discovered that sympathetic neurons of the adult nervous 
23 
 
system did undergo changes in response to inhibited NGF signaling, including 
decreases in metabolism and catecholamine synthesis, these changes were largely 
reversible once NGF signaling was restored (Figure 1.5) (Angeletti, Levi-Montalcini et 
al. 1971; Goedert, Otten et al. 1978; Otten, Goedert et al. 1979; Gorin and Johnson 
1980). 
 Interestingly, this phenomenon of increased neuronal resistance to apoptosis 
with maturation can be recapitulated in vitro. Neurons isolated from neonatal mice and 
cultured in the presence of NGF for 5 days will undergo robust apoptosis in response to 
NGF deprivation, with virtually 100% of cells dying by 72 hours post-NGF-deprivation. In 
contrast, neurons maintained in culture for 28 days are remarkably resistant to NGF 
deprivation, with >90% of cells surviving for an extended period of time in the absence 
of NGF. These mature neurons were found to undergo some of the initial steps of the 
apoptosis pathway in response to NGF-deprivation, including phosphorylation of the 
transcription factor c-jun, but never progressed to the point of Bax activation and 
mitochondrial outer membrane permeablization (MOMP) (Lazarus, Bradshaw et al. 
1976; Chun and Patterson 1977; Deshmukh and Johnson 1997; Easton, Deckwerth et 
al. 1997). These findings were also recapitulated in another peripheral neuron 
population, the Dorsal Root Ganglia (DRG) neurons, which, similar to sympathetic 
neurons, are dependent on NGF for survival early in development and lose this 
dependence as they mature (Lindsay 1988; Kimpinski, Campenot et al. 1997; 
Vogelbaum, Tong et al. 1998). Similar cases have also been observed in the central 
nervous system (CNS), where neurons of the anteroventral cochlear nucleus (AVCN), 
which stimulate the cochlea, will undergo robust apoptosis if the cochlea is removed 
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during a critical early postnatal period, but these neurons persist if the cochlea is 
removed later in development (Tierney, Russell et al. 1997; Mostafapour, Cochran et al. 
2000; Mostafapour, Del Puerto et al. 2002; Harris and Rubel 2006).  
 In addition to developmental cues, enhanced survival of mature neurons has also 
been observed following pathological or traumatic stimuli. For example, nerve 
transection has been found to cause widespread cell death in multiple neuronal 
populations in young mice, but significantly reduced cell death in neurons of older mice 
subjected to the same insult (Rich, Luszczynski et al. 1987; Yan and Johnson 1988; Yu 
1988; Snider and Thanedar 1989; Sendtner, Kreutzberg et al. 1990; Kuzis, Coffin et al. 
1999; McKernan, Caplis et al. 2006). 
 In the case of hypoxic-ischemic brain injury, it has been found that widespread 
caspase-dependent death occurs in the neonatal brain in vivo when mice are subjected 
to hypoxic ischemic insult. This death exhibits classical hallmarks of apoptosis, including 
DNA fragmentation, TUNEL staining, and the presence of apoptotic morphology 
detected by electron microscopy (Cheng, Deshmukh et al. 1998). In contrast, older mice 
subjected to the same insult show marked decreases in the number of cells exhibiting 
apoptotic morphology, as well as decreased Caspase 3 activation (Hu, Liu et al. 2000). 
 Neuronal resistance to apoptosis may also play a role in the response to viral 
infection in mammals. Many neurotropic viruses, such as rhabdoviruses, reoviruses, 
bunyaviruses, alphaviruses, herpesviruses, and flavivviruses, have been found to cause 
more severe infections and neurological symptoms in young patients when compared to 
older patients (Griffin, Levine et al. 1994; Fazakerley and Allsopp 2001; Kimberlin 
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2004). While the outcome of a viral infection depends on many factors, such as immune 
response, changes in cell-surface receptors, development of anatomical barriers, etc., 
there is evidence that increased neuronal resistance to apoptosis may also play a role 
in this acquired resistance to viral infection with increasing age. For example, infection 
of 1-day old mice with Sindbis virus leads to death of 100% of the infected mice within 8 
days, and widespread neuronal cell death in the CNS as determined by histology and 
TUNEL staining. In contrast, virus-infected 4-week old mice displayed no mortality or 
clinically apparent disease, and no increase in CNS cell death (Labrada, Liang et al. 
2002). Importantly, overexpression of the anti-apoptotic protein BCL-2 in the brains of 
neonatal mice infected with Sindbis virus significantly increased the survival of the 
infected mice (7.8% mortality vs. 72.1 and 78.1% mortality in mice infected with control 
viruses) and decreased apoptosis in infected brains (Levine, Goldman et al. 1996).  
 The observation that older neurons are more resistant to apoptosis may also 
have clinical relevance in the field of anesthesiology. Studies have found that commonly 
used anesthetic agents cause widespread apoptosis in the brains of neonatal mice, and 
that this leads to behavioral deficits in these mice later in life (Jevtovic-Todorovic, 
Hartman et al. 2003; Zhou and Ma 2014) Correlative studies examining learning and 
behavioral problems in cohorts of human patients have produced mixed results, 
however several researchers have found evidence of increased learning and behavioral 
problems in children who have undergone anesthesia early in life, particularly in those 
children who have been anesthetized multiple times (Wilder, Flick et al. 2009; DiMaggio, 
Sun et al. 2012). 
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 The precise mechanism through which anesthetics cause apoptosis in the young 
brain is has not been definitively determined. It is thought that the ability of most 
anesthetics to antagonize excitatory N-Methyl-D-Aspartate (NMDA) receptors and 
potentiate inhibitory Gamma-Aminobutyric Acid (GABA) receptor activity in the 
developing brain plays a role (Chiao and Zuo 2014). Indeed, neurons in the young brain 
have been found to be acutely sensitive to either excitation or inhibition of NMDA 
receptor activity. Excitation of NMDA receptors through direct injection of NMDA, or 
inhibition of NMDA receptors by direct injection of the NMDA antagonist MK-801 into the 
brains of developing mice were found to cause widespread apoptosis in neonatal rodent 
brains, which was decreased with increasing age (McDonald, Silverstein et al. 1988; 
Ikonomidou, Bosch et al. 1999). It is likely that changes in the relative levels of NMDA 
and GABA receptors in the brain, as well as changes in the cellular response to 
manipulation of GABA/NMDA receptor activity, play a role in this response. However, 
developmental changes in the apoptotic machinery likely also have an effect.  
 
1.8 Molecular Mechanisms Underlying Increased Neuronal Resistance to Apoptosis 
Post-Mitochondrial Apoptotic Brakes 
 Maturing neurons across the nervous system have been found to restrict cell 
death by regulating the apoptotic pathway at various points before and after 
mitochondrial outer membrane permeablization (MOMP). After MOMP, cyt c is released 
from the mitochondria and binds to the pro-apoptotic protein Apaf-1. Cyt c and Apaf-1 
then oligomerize with the activator caspase, Caspase 9, to form the apoptosome 
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complex. This complex then cleaves and activates executioner caspases, most notably 
Caspase 3/7, which cleave a large number of substrates, resulting in the ultimate death 
of the cell.  
 Evidence that apoptosis is restricted has been definitively demonstrated in the 
sympathetic neuronal model of apoptosis. As previously described, young neurons have 
been found to undergo robust cell death in response to apoptotic stimuli, while mature 
neurons have been found to be markedly resistant to apoptosis induction. To investigate 
whether mature neurons restrict apoptosis at a checkpoint after cyt c release, 
experiments were conducted utilizing microinjection of purified cyt c directly into the 
cytosol of sympathetic neurons. While cyt c injection is insufficient to induce death in 
young sympathetic neurons maintained in NGF, young neurons can be induced to 
develop so-called “competence to die” by depriving cells of NGF in the absence of Bax 
or the presence of inhibitors of protein synthesis, which arrest the apoptotic pathway 
prior to the point of cyt c release (Deshmukh and Johnson 1998). Development of 
competence depends on the inactivation and/or degradation of X-Linked Inhibitor of 
Apoptosis Protein (XIAP). XIAP is known to be able to bind to Caspase 3 and Caspase 
9 and inhibit their activity (Riedl, Renatus et al. 2001; Shiozaki, Chai et al. 2003). NGF 
deprivation leads to downregulation of XIAP levels, and neurons from XIAP-deficient 
animals are acutely sensitive to cytosolic injection of cyt c (Potts, Singh et al. 2003). 
 In contrast to young sympathetic neurons, mature neurons are not sensitive to 
cyt c microinjection, even when subjected to the same treatments that induce 
competence to die in young neurons (Putcha, Deshmukh et al. 2000).  It was found that 
mature sympathetic neurons restrict apoptosis post-mitochondrially by restricting the 
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expression of Apaf-1 at the chromatin level, preventing apoptosome formation and 
subsequent caspase activation to arrest the cell death pathway (Wright, Smith et al. 
2007). Interestingly, Apaf-1 levels have been found to decline during development in 
multiple neuronal tissues, including the cerebral cortex, cerebellum, and retina 
(Yakovlev, Ota et al. 2001; Donovan and Cotter 2002; Ota, Yakovlev et al. 2002; 
Johnson, Huang et al. 2007). This suggests that restriction of Apaf-1 expression is a 
conserved mechanism to restrict apoptosis during the maturation of multiple neuronal 
populations.  
 While maturing sympathetic neurons and dorsal root ganglion neurons have 
been found to specifically downregulate Apaf-1 while maintaining the levels of Caspase 
3 and Caspase 9, other neuronal populations have been found to restrict apoptosis by 
downregulating the expression of caspases as well. Decreases in Caspase 3 
expression with maturation have been observed in cortex, cerebellum, photoreceptors, 
and neurons of the AVCN in the brainstem (Yakovlev, Ota et al. 2001; Donovan and 
Cotter 2002; Harris, Hardie et al. 2005; Johnson, Huang et al. 2007). In the motor 
neurons of the spinal cord, it was found that the ratio of XIAP to XIAP Associated Factor 
1 (XAF1) increases with maturation. XAF1 is a protein which acts to promote apoptosis 
by restricting the ability of XIAP to inhibit caspases, and increasing the XIAP/XAF1 ratio 
enhanced the ability of XIAP to inhibit cell death and contributed to the enhanced 
resistance of mature motor neurons to axotomy when compared with younger neurons 
subjected to the same insult. Indeed, overexpression of XAF1 in mature spinal cord 
neurons was able to abrogate the resistance of these neurons to axotomy-induced 
apoptosis (Perrelet, Perrin et al. 2004).  
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 Heat shock protein 27, or HSP27, has been found to be a critical determinant in 
the survival of sensory and motor neurons in response to axotomy. In young mice 
subjected to nerve transection, it was observed that the majority of neurons in the 
transected ganglia die, but a subset survive, and the surviving neurons were found to 
express HSP27. In adult mice subjected to the same insult, a much greater percentage 
of neurons survive, and 100% of neurons were found to express HSP27, suggesting 
that the enhanced survival of DRG or motor neurons in response to axotomy is due to 
the increased ability of adult neurons to upregulate HSP27 in response to this insult 
(Costigan, Mannion et al. 1998). Overexpression of HSP27 was found to promote 
survival of young DRG neurons when delivered in vivo, while knockdown of HSP27 in 
mature DRGs was found to sensitize them to death in response to axotomy (Benn, 
Perrelet et al. 2002).  
 Interestingly, HSP27 may promote survival via different mechanisms in different 
cell types. In neurons, it was found that HSP27 prevents caspase 3 activation but not 
cyt c release (Benn, Perrelet et al. 2002). Consistent with this observation, it has been 
found that HSP27 can directly bind to and sequester cyt c and caspase 3 (Bruey, 
Ducasse et al. 2000; Concannon, Orrenius et al. 2001).  However, a separate study in 
cancer cells found that HSP27 was able to indirectly prevent Bax activation by 
promoting pro-survival AKT signaling (Havasi, Li et al. 2008).  
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Pre-Mitochondrial Apoptotic Brakes 
 Similar to other aspects of apoptosis regulation during neuronal maturation, the 
characterization of pre-mitochondrial apoptotic brakes has been most thoroughly 
performed in the model of mouse sympathetic neurons. The early stages of apoptosis in 
mouse sympathetic neurons deprived of NGF involve changes in the phosphorylation 
status of its receptor, TRKA. In response to NGF stimulation, the TRKA receptor 
becomes phosphorylated, and exerts pro-survival and trophic effects through 
stimulation of a several downstream pathways, most notably the Ras-Raf-Mek-ERK and 
PI3-Kinase pathways (Kaplan and Miller 2000).  
 Upon NGF deprivation, levels of phospho-TRKA decline, leading to diminished 
stimulation of downstream pro-survival pathways and increased stimulation of pro-death 
pathways, such as the MLK-JNK pathway described above. Interestingly, while 
phospho-TRKA levels decline rapidly in young neurons deprived of NGF, phospho-
TRKA levels have been found to decline much more slowly in mature neurons. It has 
been suggested that this increased persistence of TRKA signaling in the absence of 
NGF could contribute to the resistance to apoptosis observed with neuronal maturation 
(Tsui-Pierchala and Ginty 1999).  
 While preservation of TRKA signaling in mature neurons deprived of NGF may 
indeed play a role in the resistance of mature sympathetic neurons to apoptosis, 
evidence in the literature suggests that it is not the dominant mechanism that mature 
neurons employ to restrict cyt c release. Other studies that investigated the status of 
NGF-deprived mature neurons found that while death was arrested, a number of the 
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early events associated with NGF deprivation still proceeded as they did in young 
neurons. For example, both young and mature neurons exhibit a decrease in soma 
diameter and protein synthesis in response to NGF deprivation and both young and 
mature neurons display decreases in their rates of glucose uptake, RNA synthesis, and 
protein synthesis within the first 24 hours of NGF deprivation (Easton, Deckwerth et al. 
1997).  
 When examining the components of the apoptotic pathway more directly, it was 
found that c-jun phosphorylation, known to be a key event in the induction of apoptosis 
in sympathetic neurons, still occurred within 6 hours in mature neurons deprived of 
NGF, and persisted out to 48 hours in culture. Furthermore, induction of several genes 
found to be induced with NGF deprivation in young neurons, including cyclophilin, c-jun, 
and c-fos, still occurred in mature neurons deprived of NGF. Taken together, these 
results suggested that the early events of the apoptotic pathway in mature neurons 
were able to proceed as in young neurons, but neurons failed to die (Easton, Deckwerth 
et al. 1997). A subsequent study examined the status of Bax and cyt c in mature 
neurons induced to die by NGF deprivation, and found that while Bax localized to the 
mitochondria and induced cyt c release in young neurons, both of these events failed to 
occur in mature neurons, consistent with the findings of the study discussed above 
(Putcha, Deshmukh et al. 2000). Taken together, these two studies provided the first 
direct mechanistic evidence for the existence of apoptotic brakes upstream of Bax 
activation in mature neurons. Importantly, neither study found that mature neurons had 
changes in the expression level of Bax itself. The efficacy of restricting Bax activation as 
a mechanism for inhibiting death in mature neurons is underscored by the finding that 
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Bax-knockout neurons are capable of surviving long-term in the absence of any trophic 
stimulation (Deckwerth, Elliott et al. 1996). 
 In contrast to sympathetic neurons, some other neuronal populations appear to 
repress Bax activation as they mature. Bax expression has been found to decline during 
the maturation of cerebellum, dorsal root ganglia, and forebrain neurons (Vekrellis, 
McCarthy et al. 1997; Vogelbaum, Tong et al. 1998; Polster, Robertson et al. 2003). 
Interestingly, in the case of forebrain neurons, it was found that a percentage of Bax is 
present at the mitochondrial outer membrane of purified mitochondria in the absence of 
any apoptotic stimulus, and that the amount of Bax present at the outer membrane 
declined with maturation. This correlated strongly with decreasing ability of purified 
mitochondria to release cyt c in response to incubation with purified Bax-BH3-only 
peptide, and suggests that Bax may exist at the mitochondria of young neurons in a 
“primed” state that increases the sensitivity of cells to apoptosis.  
 The findings summarized above highlight the increasing resistance of diverse 
populations of neuronal cells to apoptosis as they mature. The fact that different 
populations of neurons restrict the pathway in different ways (e.g. repressing Bax vs 
expressing Bax with maturation) suggests that apoptotic proteins may perform other 
functions. Indeed, it has been found recently that activation of caspase 3 in a limited 
fashion is required for Long-Term Depression (LTD) and AMPA receptor internalization 
in hippocampal neurons (Li, Jo et al. 2010) . Thus, different populations of neurons may 
restrict apoptosis in different ways depending on their specific stresses and 
requirements for apoptotic proteins to perform non-apoptotic functions.   
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1.10 Introduction to miR-29 
 The miR-29 family of miRNAs are of particular interest to the study of neuronal 
maturation and apoptosi. The miR-29 family is composed of 3 members: miR-29a, miR-
29b, and miR-29c. These family members are transcribed from two separate 
chromosomes in humans and mice. miR-29a and miR-29b1 are cotranscribed from 
chromosome 7, while miR-29b2 and miR-29c are cotranscribed from chromosome 1. 
miR-29b1 and b2 are identical in sequence and are collectively referred to as miR-29b 
in their mature form. The three family members share a conserved seed sequence, 
which is thought to be important for target selectivity and specificity.  
 The miR-29 family is widely expressed and is one of the more extensively 
studied microRNAs to date. It has been identified as playing a role in regulating a 
diverse range of cellular pathways, including innate/adaptive immune response (Ma, Xu 
et al. 2011) (Ma et al., 2011), lipid metabolism (Kurtz, Peck et al. 2014), and the 
regulation of various extracellular matrix components, such as collagen proteins, in the 
fibrosis of various tissues such as lung (Xiao, Meng et al. 2012; Montgomery, Yu et al. 
2014)(Montgomery et al., 2014; Xiao et al., 2012), kidney (Qin, Chung et al. 2011), and 
heart (van Rooij, Sutherland et al. 2008). Of particular interest to this dissertation, 
however, is the role that miR-29 has been found to play in the regulation of apoptosis.  
 The ability of miR-29 to regulate apoptosis was first discovered in 2007, when it 
was found that the anti-apoptotic BCL-2 family protein MCL-1 contained a putative miR-
29 binding site in its 3 ’UTR. It was found that miR-29b was highly expressed in a 
healthy bile-duct epithelium cell line, while malignant bile-duct epithelium cells, known 
as cholangiocarcinoma cells, miR-29b levels were decreased. Enforced expression of 
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miR-29 in malignant cells was found to reduce MCL-1 protein levels and sensitize these 
cells to Tumor Necrosis Factor-induced apoptosis, while transfection of non-malignant 
cells with a Locked-Nucleic Acid (LNA) designed to inhibit miR-29 activity resulted in 
increased MCL-1 levels and decreased sensitivity to apoptosis (Mott, Kobayashi et al. 
2007). Consistent with a pro-apoptotic role for miR-29 in cancer, miR-29 has been 
found to be suppressed or deleted in a number of cancer types, including Acute Myeloid 
Leukemia (Eyholzer, Schmid et al. 2010), Mantle Cell Lymphoma (Zhang, Zhao et al. 
2012), and B-Cell Chronic Lymphocytic Leukemia (Pekarsky, Santanam et al. 2006). 
miR-29 was also found to promote p53 expression and apoptosis in HeLa cells by 
downregulating P85-alpha and CDC42, which are two proteins that negatively regulate 
p53 (Park, Lee et al. 2009).  
miR-29 miRNAs as Regulators of Neuronal Apoptosis 
 Recently, it has been found that mature sympathetic neurons fail to upregulate 
BH3-only domain genes in response to NGF deprivation (Kole, Swahari et al. 2011). 
The same study found that maturing neurons of multiple neuronal populations 
upregulate members of the miR-29 family of microRNAs, miR-29a, miR-29b, and miR-
29c. It was found that each of the BH3-only genes that are typically upregulated with 
NGF deprivation in sympathetic neurons, namely Bim, BMF, Puma, and HRK, 
possessed a sequence that was complimentary to the miR-29 seed sequence in its 
3’UTR. Luciferase reporter assays, performed by cloning the 3’UTRs of these genes 
into a luciferase reporter vector and measuring the ability of transfected miRNA mimics 
to inhibit luciferase transcription, validated the ability of miR-29 to bind these sites in 
vitro. Most importantly, it was found that overexpression of the miR-29 family member 
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miR-29b in young neurons was able to provide significant protection for those neurons 
against diverse apoptotic insults, including NGF deprivation, DNA damage, and 
Endoplasmic Reticulum stress (Kole, Swahari et al. 2011). microRNAs, with their ability 
to simultaneously target multiple different genes in the same pathway, provide an 
attractive candidate for regulation of the redundant members of the BH3-only domain 
proteins in maturing neurons. 
 Studies performed in other labs further strengthened the case for the miR-29 
family as promoters of neuronal survival. miR-29b was found to be decreased in the 
infarct area of mice subjected to brain ischemia by middle cerebral artery occlusion 
(MCAO), and exogenous expression of miR-29b mimics resulted in a significant 
decrease in infarct size. Furthermore, mice treated with miR-29b mimics prior to MCAO 
exhibited improved sensorimotor function and behavioral outcome post-stroke (Khanna, 
Rink et al. 2013).  A separate study examined the regulation of the miR-29 family in the 
ischemic hippocampus and found that miR-29a was selectively downregulated, and that 
overexpression of miR-29a was able to preserve astrocyte survival and function during 
ischemia by inhibiting Puma induction (Ouyang, Xu et al. 2013). miR-29 levels have 
also been reported to be decreased in injured mouse spinal cord, and that addition of 
miR-29 mimics could partially rescue the apoptosis that occurred in response to spinal 
cord injury. This apoptosis could be completely abolished if the miR-29 mimics were co-
transfected with inhibitors to miR-20a, a pro-apoptotic miRNA that increased in the 
lesioned spinal cord (Liu, Zheng et al. 2015). 
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miR-29 may also regulate neuronal apoptosis through mechanisms independent of its 
ability to target BH3-only genes. A recent study examining the effects of ethanol on cell 
death in the developing cerebellum found that mir-29 levels were decreased in neurons 
exposed to ethanol, and that exogenous expression of miR-29 could dramatically 
decrease cell of cerebellar granule neurons treated with ethanol. Interestingly, the 
authors noted that they observed no effect of miR-29 mimic expression on BH3-only 
gene levels in cerebellar granule neurons, and that this protection instead was mediated 
by inhibition of an SP1-RAX-PKR cascade by miR-29 (Qi, Zhang et al. 2014)(Qi and 
Zhang et al., 2014). Additionally, a recent study identified Aquaporin 4 as another 
potential target of miR-29 that at least partially mediates its neuroprotective effects 
during ischemia (Wang, Huang et al. 2015). The apparently opposite effects of miR-29 
upregulation on apoptosis in cancer cells and neurons may be due to differential 
dependence of these different cell types on MCL-1 for survival. They may also be due to 
the effect of miR-29 on downregulating cell cycle gene expression, such as CDK6 
(Zhao, Lin et al. 2010). Inhibition of cell-cycle progression can lead to cell-cycle arrest 
and apoptosis in mitotic cells, but has been found to be protective in neurons.  
 The findings summarized above raise many interesting questions. Firstly, miR-29 
upregulation is the only brake identified so far that neurons can employ to block 
apoptosis upstream of cyt c release. Is miR-29 the only brake that blocks this event in 
mature neurons? Do neurons lacking miR-29 survive the maturation process? Are 
mature neurons lacking miR-29 more vulnerable than wild-type neurons to apoptotic 
insults? Are other miRNAs upregulated during nervous system maturation, and can they 
play a role in regulating apoptosis? What regulates the up/downregulation of various 
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apoptotic components that change their expression level to render mature neurons 
more resistant to apoptosis? This dissertation supplies answers to some of these 
questions, and raises new questions that will remain under investigation as the study of 
neuronal apoptosis continues. 
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1.11 Figures and Legends 
Figure 1.1: The BCL-2 Family of Proteins 
The BCL-2 family can be broken down into three subgroups based on structure and 
function. The anti-apoptotic members of the family contain BH1-BH4 domains. The pro-
apoptotic members can be further subdivided into the multidomain pro-apoptotic 
proteins and the BH3-only domain proteins. The multidomain pro-apoptotic proteins Bax 
and Bak lack BH4 domains and are essential for the permeablization of the 
mitochondrial outer membrane to release cytochrome c. BH3-only domain proteins , as 
their name suggests, express only BH3 domains and promote apoptosis by either 
activating Bax and Bak or inhibiting the activity of the anti-apoptotic BCL-2 family 
members. 
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Figure 1.1: The BCL-2 Family of Proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from (Taylor, Cullen et al. 2008) 
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Figure 1.2: Effector and Initiator Caspases 
Domain structure of effector caspases (Caspase 3, 6, 7) and initiator caspases 
(Caspase 2, 8, 9, 10).  Cleavage sites are indicated by black arrows, while alternate 
cleavage sites, thought to be important for caspase regulation, are indicated with gray 
arrows. Catalytic cysteines are indicated in red. Death Effector Domains (DED) are 
important for participation in the extrinsic apoptotic pathway, while Caspase Activation 
and Recruitment Domains (CARD) are important for participation in the intrinsic 
apoptotic pathway. Members of the caspase family thought to be more important for 
inflammatory cell death (e.g. Caspase 1) are not pictured.  
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Figure 1.2: Effector and Initiator Caspases 
 
Adapted from (Riedl and Shi 2004)  
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Figure 1.3: Timecourse of Developmental Milestones in Sympathetic Neuron 
Development 
Figure 1.3 shows the timecourse of the key events in the formation of the sympathetic 
nervous system. Proper formation of the nervous system requires neurons to properly 
migrate, differentiate, and make connections with the proper targets, often 
simultaneously, with cells that fail do any of the above pruned from the population by 
apoptosis. Adapted from (Glebova and Ginty 2005). 
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Figure 1.3: Timecourse of Developmental Milestones in Sympathetic Neuron 
Development 
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Figure 1.4: Apoptosis is Essential for Proper Brain Development 
Inhibition of apoptosis during development leads to defects in brain morphology and 
embryonic lethality. Mice deficient in Caspase-9 (Panel B) or Apaf-1 (Panel C) exhibit 
brain and craniofacial defects during embryonic development when compared to wild-
type mice. Caspase 9 knockout embryos are age E16.5, while Apaf-1 knockout 
embryos are age E13.5.  
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Figure 1.4: Apoptosis is Essential for Proper Brain Development 
 
Adapted from (Kuida, Haydar et al. 1998; Yoshida, Kong et al. 1998)  
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Figure 1.5: The Intrinsic Apoptotic Pathway in Sympathetic Neurons 
In sympathetic neurons, apoptotic stimuli, such as growth factor deprivation, lead to the 
activation of Mixed Lineage Kinases (MLKs). MLKs then phosphorylate and activate 
members of the c-Jun N-Terminal Kinase (JNK) family of proteins, which phosphorylate 
the transcription factor c-Jun. Upon phosphorylation, c-Jun translocates from the 
cytoplasm to the nucleus, where it cooperates with other transcription factors to 
upregulate multiple redundant members of the pro-death BH3-only domain family of 
proteins. Increased levels of BH3-only proteins promote apoptosis both by directly 
activating Bax and neutralizing the anti-apoptotic members of the BCL-2 family (BCL-2, 
BCL-XL, BCL-w, and MCL-1) which oppose Bax activation. Once activated, Bax 
undergoes conformational changes, resulting in its oligomerization and translocation to 
the mitochondria, where it mediates the permablization of the outer mitochondrial 
membrane and the release of the electron transport chain protein cytochrome c (cyt c) 
into the cytoplasm. Once in the cytoplasm, cyt c forms the apoptosome complex with 
Apaf-1 and procaspase 9, resulting in procaspase 9 cleavage and activation. Active 
Caspase 9 then cleaves Caspase 3, which in turn cleaves a large number of 
downstream substrates, ultimately resulting in the death of the cell.  
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Figure 1.5: The Intrinsic Apoptotic Pathway in Sympathetic Neurons 
 
 
 
 
 
 
 
 
 
 
 
48 
 
Figure 1.6: Overview of miRNA Biogenesis and Function 
miRNAs are transcribed from genomic DNA by RNA Polymerase II to generate pri-
miRNAs, which are then cleaved by Drosha and DGCR8 to generate pre-miRNAs. Pre-
miRNAs are in turn exported from the nucleus via an Exportin-5-dependent process, 
where they are further cleaved by Dicer to generate mature miRNAs. These miRNA 
duplexes are loaded into the RISC Complex, after which one strand, the passenger 
strand, is removed and degraded, leaving the other strand, the guide strand, bound to 
the RISC complex. The miRNA in the RISC complex binds to target mRNAs and 
mediates their post-transcriptional repression via RNA degradation or translational 
repression. 
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Figure 1.6: Overview of microRNA Biogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from (Winter, Jung et al. 2009) 
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Figure 1.7: Resistance of Sympathetic Neurons to Apoptosis with Maturation 
Neonatal mice injected with a neutralizing antibody to NGF (Panel A, Ganglion E) 
exhibit dramatic atrophy compared to control-injected mice (Panel A, Ganglion C). In 
contrast, adult mice injected with a neutralizing antibody to NGF (Panel B, Ganglion E) 
display markedly reduced atrophy compared to ganglia from control injected mice 
(Panel B, Ganglion C).  
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Figure 1.7: Resistance of Sympathetic Ganglia to Apoptosis with Maturation 
 
Adapted from Levi-Montalcini and Booker, 1960 and Angeletti et al., 1970 
 
  
 
 
 
 
 
 
 
 
 
 
52 
 
1.14 Tables 
Table 1.1: miRNAs in Neurodegeneration and Stroke 
 
Disorder miRNA Status Mechanism Citation 
Alzheimer's 
Disease miR-107 Decreased 
Targets BACE1 to 
inhibit Beta-Amyloid 
Production Wang et al., 2008 
      Targets Cofilin Yao et al., 2010 
  miR-29  Decreased 
Targets BACE1 to 
inhibit Beta-Amyloid 
Production Hebert et al., 2008 
  miR-298 
Decreased 
(Mouse) 
Targets BACE1 to 
inhibit Beta-Amyloid 
Production 
Boissonneault et 
al., 2009 
  miR-328 
Decreased 
(Mouse) 
Targets BACE1 to 
inhibit Beta-Amyloid 
Production 
Boissonneault et 
al., 2009 
  miR-15a Decreased 
Targets ERK1, which is 
can phosphorylate Tau.  Hebert et al., 2010 
  miR-153 Decreased 
Represses expression 
of APP. Long et al., 2012 
Huntington's 
Disease 
miR-
9/9* Decreased 
Represses expression 
of REST/CoREST. Packer et al., 2008 
Parkinson's 
Disease miR-7 Decreased Targets α-Synuclein Junn et al., 2009 
  miR-34 Decreased 
Deletion leads to 
neurodegeneration in 
Drosophila. 
Minones-Moyano 
et al., 2011 
  miR-433 
Target 
Mutated 
Increased FGF20 
Expression leads to 
increased α-Synuclein 
expression. Wang et al., 2008 
ALS miR-206 Increased 
Slows ALS progression 
by inhibiting HDAC4 
and FGF Pathways. 
Williams et al., 
2009 
Stroke miR-21 Increased 
Targets and 
downregulates FASLG. Buller et al., 2010 
  
miR-
124a Increased 
Mimic delivery 
decreases infarct area 
and apoptosis Sun et al., 2013 
  miR-29 Decreased 
miR-29 mimic delivery 
decreases infarct size 
and improves 
behavioral outcomes. Khanna et al., 2013 
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CHAPTER 2:  MATURE NEURONS DYNAMICALLY RESTRICT APOPTOSIS VIA 
REDUNDANT PRE-MITOCHONDRIAL BRAKES 
 
2.1: Introduction 
In recent years, it has become increasingly clear that the threshold to undergo 
apoptosis can be markedly different in different cell types.  For example, primary mitotic 
cells are sensitive to apoptotic insults, whereas postmitotic cells such as neurons, 
cardiomyocytes and myotubes have acquired mechanisms for restricting apoptosis 
(Benn, Perrelet et al. 2002; Potts, Singh et al. 2003; Sanchis, Mayorga et al. 2003; 
Mayorga, Bahi et al. 2004; Nam, Mani et al. 2004; Wright, Linhoff et al. 2004; Potts, 
Vaughn et al. 2005; Wright, Smith et al. 2007; Vaughn and Deshmukh 2008; Smith, 
Huang et al. 2009; Kole, Swahari et al. 2011; Xiao, Ferry et al. 2011; Gama, Swahari et 
al. 2014; Oláh, Szczesny et al. 2015). Such differences in the regulation of apoptosis 
are physiologically important because while mitotic cells are at continual risk of 
becoming cancerous and need to maintain their ability to die rapidly, this risk is 
significantly lower in terminally differentiated postmitotic cells.  Indeed, the ability of 
organisms to maintain the long‐term survival of postmitotic cells such as neurons is 
critical for normal physiological functions (Wright et al., 2002).    
What is less appreciated is that even within the same cells, the apoptotic pathway 
can sometimes undergo dynamic changes during and after development. A cell type 
that exemplifies this phenomenon is neurons, where the apoptotic pathway becomes 
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highly restricted as young neurons become mature (Kole, Annis et al. 2013). Apoptosis 
plays an important role in the developing nervous system, where it is estimated that 
more than 50% of neurons that are initially produced will die by apoptosis as a part of 
normal neuronal development (Oppenheim 1991). However, once the nervous system 
is fully formed and neurons are appropriately wired, it is physiologically important for 
these neurons to survive long term. Indeed, the apoptotic pathway becomes highly 
restricted with neuronal maturation, but the molecular details are not completely 
understood. 
Mouse sympathetic neurons provide an excellent model system for studying the 
regulation of the apoptotic pathway during neuronal maturation.  Young P5 (postnatal 
day 5) neurons can undergo apoptosis in response to multiple stimuli including nerve 
growth factor (NGF) withdrawal, DNA damage, and Endoplasmic Reticulum stress. In 
contrast, those same neurons after 4-5 weeks (P28) become remarkably resistant to the 
same apoptotic stimuli (Kole et al., 2011; Easton et al., 1997; Putcha et al., 2000).  
Apoptotic stimuli in neurons are known to transcriptionally upregulate multiple redundant 
members of the pro-apoptotic BH3-only family of proteins (Kristiansen et al., 2011). 
These proteins activate Bax, which then permeablizes the mitochondria to induce the 
release of cytochrome c (cyt c) into the cytosol (Putcha, Deshmukh et al. 2000; Ham, 
Towers et al. 2005). Once in the cytosol, cyt c binds to Apaf-1 (Apoptotic Activating 
Protease 1) and forms the apoptosome complex with procaspase-9.  Autoactivation of 
caspase-9 on the apoptosome can then activate caspase-3 to ultimately trigger cell 
death (Wang 2001).  
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We and others have previously shown that one mechanism by which mature 
neurons become resistant to apoptosis is via the epigenetic silencing of Apaf-1(Wright 
et al., 2007; Donovan and Cotter, 2002; Madden et al., 2007; Yakovlev et al., 2001). 
However, mature neurons induced to undergo apoptosis with NGF deprivation fail to 
release cyt c, (a process that is unaffected by Apaf-1 levels), despite maintaining Bax 
levels (Easton et al., 1997; Putcha et al., 2000). Interestingly, mature neurons still 
undergo the initial steps in the apoptotic pathway, such as c-jun phosphorylation, after 
NGF deprivation (Easton et al., 1997). This suggested the presence of one or more 
brakes upstream of cyt c release but downstream of c-jun phosphorylation in mature 
neurons. Indeed, mature neurons were found to have markedly elevated levels of the 
microRNA (miRNA) miR-29, which targets and represses multiple redundant members 
of the BH3-only family of proteins (Kole et al., 2011). A neuroprotective role for miR-29 
is further supported by the results of in vivo models of neuronal insult, which have found 
that overexpression of miR-29 is able to reduce cell death in ischemic stroke (Khanna, 
Rink et al. 2013; Ouyang, Xu et al. 2013; Pandi, Nakka et al. 2013), spinal cord injury 
(Liu et al., 2015), and ethanol-induced  toxicity (Qi et al., 2014).  However, it is unclear 
at this point whether miR-29 induction is the only brake employed to inhibit cyt c release 
in mature neurons, or if other redundant brakes also exist.  
We find that deletion of all three miR-29 family members fails to re-sensitize mature 
neurons to apoptosis, with mature miR-29 knockout neurons remaining significantly 
resistant to cyt c release induced by NGF deprivation. Here we report that another 
miRNA, miR-24, is also upregulated with neuronal maturation and is capable of acting 
redundantly with miR-29 to inhibit cyt c release by targeting a similar subset of BH3-only 
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genes. Our results highlight the ability of mature neurons to engage multiple, redundant 
mechanisms to restrict the apoptotic pathway and help ensure their long-term survival.  
 
 
2.2 Results 
Maturing neurons simultaneously restrict apoptosis both pre- and post- 
mitochondria 
In previous studies of neuronal maturation, the mechanisms by which mature 
neurons become resistant to apoptosis have been investigated in post-natal day 28 
neurons. At this time-point, neurons engage multiple mechanisms to restrict apoptosis 
both up-stream and down-stream of mitochondrial permeablization. However, the exact 
timing for when these brakes are initiated during the maturation process is not known.  
Therefore, to investigate the time course and mechanisms by which neurons become 
resistant to apoptosis with maturation, we matured neurons for increasing lengths of 
time and assessed their susceptibility to apoptotic stimuli.  Sympathetic neurons were 
isolated from neonatal (postnatal day 0-1) mouse pups and maintained in culture for 5-
25 days.  Apoptosis was then induced by deprivation of Nerve Growth Factor (NGF). 
While neurons maintained in culture for 5-7 days remained vulnerable to NGF 
deprivation-induced apoptosis, marked resistance to apoptosis was observed by as 
early as 9 days in vitro (DIV) (Figure 2.1A, B).  
Neurons have been previously shown to restrict apoptosis both before and after the 
mitochondrial checkpoint.  To more precisely define whether these two separate brakes 
were engaged simultaneously or sequentially, we specifically assessed apoptosis 
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restriction at the pre- and post-mitochondrial checkpoint. First, to assess the post-
mitochondrial resistance to apoptosis, we microinjected maturing neurons with purified 
cyt c.  These experiments were conducted in neurons from XIAP-deficient mice as XIAP 
(X-Linked Inhibitor of Apoptosis) is known to inhibit cyt c-induced apoptosis even in 
young neurons (Potts et al., 2003).  As reported earlier, neurons (XIAP-/-) maintained for 
5 DIV exhibited massive cell death in response to cytosolic cyt c injection, with virtually 
100% of neurons dying within 24 hours of injection.  Approximately 50% of neurons 
became resistant to cyt c injections by 10 DIV, with greater than 80% exhibiting 
resistance by 15 DIV (Figure 2.1C). 
Second, to assess pre-mitochondrial resistance to apoptosis, we subjected 
maturing neurons to NGF deprivation and assessed whether cyt c was maintained at 
the mitochondria or released into the cytosol by immunofluorescence.  As 
mitochondrially-released cyt c is rapidly degraded in neurons, loss of cyt c signal is an 
established indicator of its release from mitochondria in these cells (Gama et al., 2014).    
Consistent with the results of our neuronal survival experiments, neurons by 10 DIV 
exhibited significant resistance to NGF-deprivation induced cyt c release, with 
approximately 50% of neurons maintaining cyt c after 48 hrs of NGF deprivation.  Nearly 
complete resistance at this pre-mitochondrial checkpoint was seen in 15 DIV neurons 
(Figure 2.1D, E).  Together, these results show that both pre- and post-mitochondrial 
brakes are engaged concurrently in maturing neurons, resulting in resistance to 
apoptosis within 2 weeks in culture. 
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Loss of miR-29 is not sufficient to re-sensitize mature neurons to apoptosis 
Recent studies in our lab have identified the miR-29 family as regulators of 
apoptosis in maturing neurons. miR-29 is induced during neuronal maturation (Figure 
2.2A), and can inhibit the induction of multiple members of the BH3-only family of 
proteins to prevent Bax activation and apoptosis (Kole et al., 2011). We hypothesized 
that loss of miR-29 expression may render mature neurons sensitive to apoptosis. miR-
29 has three family members (miR-29a,b,c) that are expressed from two separate 
genomic loci.  Thus, to completely delete miR-29 in sympathetic neurons, mice floxed at 
both miR-29 loci were crossed with a mouse line expressing Cre recombinase under a 
tamoxifen inducible promoter (ER-Cre).  Neurons isolated from these mice were then 
treated with 4-hydroxy-tamoxifen in vitro to induce recombination and generate miR-29 
deficient neurons. Loss of miR-29 expression was verified by RT-qPCR comparing cre-
positive (hereafter referred to as miR-29 KO) and Cre-negative (hereafter referred to as 
miR-29 WT) littermates, with mature miR-29 KO neurons exhibiting virtually no 
detectable miR-29 as compared to WT controls (Figure 2.2B).  
 miR-29 WT and miR-29 KO neurons were matured in culture until 35 DIV and 
subjected to NGF deprivation to induce apoptosis. Since miR-29 is known to inhibit 
apoptosis upstream of the mitochondria (and mature neurons are known to engage an 
additional brake downstream of mitochondria), we specifically examined mitochondrial 
release of cyt c as a readout for these experiments. We were surprised to find that 
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mature miR-29 KO neurons still exhibited negligible cyt c release in response to NGF 
deprivation (Figure 2.2C, D).  
 Since miR-29 is known to be able to target multiple pro-apoptotic BH3-only 
domain genes and inhibit their induction, we next assayed BH3-induction in young wild-
type, mature wild-type, and mature miR-29 knockout neurons. Consistent with our 
findings that mature miR-29 knockout neurons fail to release cyt c, we found that miR-
29 knockout neurons also failed to substantially induce BH3-only domain genes in 
response to 48 hours of NGF deprivation when compared to young neurons as 
measured by RT-qPCR (Figure 2.2E). These results indicate that loss of miR-29 
expression alone is not sufficient to re-sensitize mature neurons to apoptosis, and led 
us to hypothesize that other brakes could be acting redundantly with miR-29 to the 
induction of BH3-only genes, cyt c release, and apoptosis in mature neurons.  
 
Other microRNAs with predicted targets in the apoptotic pathway are upregulated 
during neuronal maturation 
To identify other miRNAs that are induced during maturation and capable of acting 
redundantly with miR-29 to inhibit cyt c release and apoptosis, we utilized two 
approaches (Figure 2.3A).  First, we used TargetScan software (www.targetscan.org) to 
identify predicted miRNAs that could target the BH3-only genes.  Second, we reviewed 
existing literature on miRNAs that are known to increase with brain maturation, in 
addition to performing small-RNA-Seq on maturing cerebellum, to identify miRNAs that 
were upregulated in maturing neurons. While the fold increase in miR-29 was the most 
60 
 
striking (Figure 2.2A, Table 2.1), we identified three other miRNAs upregulated more 
than 5-fold in maturing neurons that were predicted to target the 3’ UTRs of multiple 
BH3-only family genes: miR-24, miR-124, and miR-128 (Figure 2.3B). We confirmed the 
upregulation of these miRNAs during neuronal maturation using RT-qPCR in developing 
cerebellum (Figure 2.3C-E) and sympathetic neurons (Figure 2.3F-H). These results 
identify miR-24, miR-124, and miR-128 as potential candidates that could act 
redundantly with miR-29 to restrict apoptosis in mature neurons.  
 
Overexpression of miR-24 in Young Neurons Inhibits Cyt c Release and Cell 
Death 
To determine whether any of the selected miRNAs were capable of inhibiting BH3-
only gene induction and cell death in a manner similar to miR-29, we overexpressed 
mimics to the selected miRNAs in young neurons using single-cell microinjection. 
Neurons isolated from neonatal mice were injected at 3 DIV with selected mimics or 
negative control miRNA and, after 48 hours, were deprived of NGF to induce apoptosis. 
As a positive control, we also injected neurons with a mimic to miR-29b which, as 
reported previously, inhibited cyt c release in young neurons. Among the candidate 
miRNAs, we found only miR-24 overexpression to be capable of inhibiting cyt c release 
in neurons deprived of NGF (Figure 2.4A, B).  The ability of miR-24, but not miR-124 
and miR-128, to inhibit cyt c release is likely because miR-24 is predicted to target more 
members of the redundant BH3-only family than either miR-124 or miR-128 (Figure 
2.3B).  Importantly, we also examined whether miR-24 expression could inhibit 
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apoptosis.  Consistent with the observed effect on cyt c release, we found that miR-24 
significantly inhibits apoptosis in NGF-deprived young neurons (Figure 2.4C).  
 
miR-24 Can Inhibit Bim and Puma Induction in NGF-Deprived Neurons 
While previously published reports have validated miR-24 binding sites in the Bim 
3’UTR, and miR-24 has been previously shown to downregulate Bim expression and 
inhibit apoptosis in cardiac tissue (Qian et al., 2011), its potential role in regulating 
neuronal apoptosis has not been investigated. To examine if miR-24 could inhibit Bim 
induction in neurons, young (P3 equivalent) sympathetic neurons were injected with 
mimics to miR-24, miR-29 (positive control), or a negative control miRNA, and were 
then subjected to NGF deprivation to trigger Bim induction. Just as seen with miR-29, 
miR-24 expression potently suppressed Bim induction in NGF-deprived neurons (Figure 
2.5A, B).  
 We next sought to determine if miR-24 could also target Puma, another BH3-only 
family member that has been found to act redundantly with Bim to induce neuronal 
apoptosis (Ren et al., 2010). Puma has two conserved miR-24 sites in its 3’UTR (Figure 
2.5C). To validate these sites, we cloned the 3’UTR of Puma into a luciferase reporter 
vector. We then cotransfected this vector with either a negative control miRNA or a miR-
24 mimic into HEK293T cells. We found that miR-24 was indeed able to significantly 
repress the expression of luciferase in cells expressing the Puma 3’UTR compared to a 
negative control (Figure 2.5D).  
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 To test the functional ability of miR-24 expression to inhibit Puma, we took 
advantage of the fact that in sympathetic neurons, cyt c release and apoptosis in 
response to DNA damage is known to be entirely dependent on Puma expression 
(Wyttenbach and Tolkovsky 2006). Thus, we examined whether miR-24 expression was 
able to effectively inhibit cyt c release in young neurons treated with the DNA damaging 
agent etoposide.  Consistent with our observation that miR-24 is able to target Puma, 
we found that the release of cyt c was inhibited in young neurons expressing miR-24 in 
response to etoposide treatment (Figure 2.5E, F).  Together, these results identify miR-
24 as a miRNA that is not only induced with neuronal maturation, but as seen with miR-
29, also targets multiple BH3-only genes and inhibit neuronal apoptosis. 
Inhibition of miR-24 in miR-29-deficient neurons leads to partial restoration of 
apoptotic response 
Given our observation that miR-24 is induced in mature neurons and is able to target 
similar BH3-only genes as miR-29, we hypothesized that miR-24 and miR-29 may act 
redundantly to inhibit the release of cyt c in mature neurons.  Thus, we sought to 
determine if inhibition of miR-24 function in mature miR-29 KO neurons would render 
these cells more sensitive to apoptosis. Mature miR-29 KO neurons were injected with a 
locked nucleic acid (LNA) targeting miR-24 designed to inhibit its activity, or a negative 
control LNA. Neurons were then deprived of NGF and the status of cyt c release was 
quantified using immunofluorescence. Inactivation of miR-24 and miR-29 together 
rendered mature neurons more sensitive to NGF deprivation than seen with miR-29 
deficiency alone (Figure 2.6 A, B).  However, the majority of mature neurons still failed 
to release cyt c, raising the possibility that yet more redundant brakes likely exist to 
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restrict the apoptotic pathway in mature neurons. Indeed, when we examined whether 
mature sympathetic neurons express nuclear phospho-c-jun, an early marker for 
engagement of the apoptotic pathway, we found that while the vast majority of young 
neurons exhibit nuclear phospho-c-jun at this timepoint, only a small fraction mature 
neurons did (Figure 2.6 C, D).  
 
2.3: Discussion 
 The ability of maturing neurons to dynamically switch the apoptotic pathway from 
a permissive to a restrictive state is of critical importance.  This allows young neurons to 
permit physiological apoptosis during nervous system development, but once 
established, to highly restrict apoptosis to promote the long term survival of mature 
neurons.  Previous studies had identified miR-29-mediated inhibition of BH3-only genes 
and the epigenetic silencing of the Apaf-1 promoter as mechanisms by which apoptosis 
is restricted pre- and post-mitochondria in mature sympathetic neurons (Wright et al., 
2007; Kole et al., 2011).  Our results now highlight the finding that the apoptotic 
pathway is even more restricted in adult neurons than previously appreciated, with 
mature neurons engaging redundant brakes at the pre-mitochondrial checkpoint.   
 Our previous results brought focus on the neuroprotective capability of miR-29 in 
mature neurons.  Not only is miR-29 markedly induced with neuronal maturation but 
expression of miR-29 alone is sufficient to inhibit apoptosis in young neurons by its 
ability to target the BH3-only gene family.  Delivery of miR-29 can also confer 
neuroprotection in models of stroke and spinal cord injury and alcohol-induced toxicity in 
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vivo (Ouyang et al., 2013; Khanna et al., 2013; Pandi et al, 2013; Liu et al., 2015; Qi et 
al., 2014). Our results now show that while overexpression of miR-29 promotes 
neuronal survival, loss of miR-29 failed to restore the ability of mature neurons to 
release cyt c in response to NGF-deprivation. Thus, endogenous miR-29 does not seem 
to be the only brake restricting apoptosis at the pre-mitochondrial checkpoint in mature 
neurons.  These results prompted us to identify other brakes that function redundantly 
with miR-29 to effectively inhibit apoptosis in mature neurons.   
 Our finding that miR-24 is upregulated in maturing cerebellum and sympathetic 
neurons is consistent with recent findings that miR-24 expression is up-regulated in 
maturing cerebral cortex (Chen, Xu et al. 2014). miR-24 is also a miRNA that has been 
found to be a key regulator of apoptosis in ischemic heart muscle through its ability to 
target Bim, a BH3-only protein also known to be important for neuronal apoptosis (Qian, 
Van Laake et al. 2011).The observation that the upregulation correlates with an 
increase in resistance to apoptosis made miR-24 an attractive candidate as a molecule 
that may act redundantly with miR-29 to inhibit apoptosis. Indeed, our results show that 
expression of mir-24 in young sympathetic neurons can target the BH3-only proteins 
Bim and Puma, which are thought to be the two most important BH3-only proteins for 
neuronal cell death (Ren et al., 2010), and inhibit apoptosis at the level of cyt c release.  
It is also interesting to note that miR-24 is expressed in two separate clusters with two 
other miRNAs, miR-23a/b and miR-27a/b. Recent studies have found that miR-23a/b 
and miR-27a/b are also capable of inhibiting neuronal apoptosis in cases of traumatic 
brain injury or ischemia (Chen, Xu et al. 2014; Sabirzhanov, Zhao et al. 2014). Thus, 
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miRNAs of this cluster may work synergistically to inhibit the apoptotic pathway in the 
adult brain.   
 Our finding that inhibition of miR-24 in miR-29 knockout neurons has only a 
marginal effect on the ability of neurons to release cytochrome c in response to NGF 
deprivation suggests the presence of further redundant brakes in mature neurons that 
restrict apoptosis. Our finding that c-jun-phosphorylation is decreased in mature 
neurons is consistent with this. This decrease in c-jun-phosphorylation may be due to 
prolonged TRK-A phosphorylation in mature neurons (Tsui-Pierchala and Ginty 1999), 
or may represent another, as yet uncharacterized apoptotic brake engaged in mature 
neurons. These results differ from those previously published in Rat sympathetic 
neurons (Easton, Deckwerth et al. 1997), and may reflect interspecies differences in the 
regulation of apoptosis in mature neurons.  
 Increased resistance to apoptosis with maturation has been observed in many 
populations of neurons in response to diverse insults.  For example, the neonatal brain 
is far more vulnerable to hypoxia ischemia-induced apoptosis or traumatic brain injury 
than the adult brain (Hu et al., 2000). Likewise, greater numbers of neurons survive 
nerve crush or axotomy if the injury is done on 3-week-old mice as compared to 1-
week-old mice (Snider et al., 1992).  Our work provides mechanistic insight into the 
multiple brakes engaged by mature neurons that allow these cells to withstand diverse 
stresses and survive long-term.   
 An interesting question here is why do mature neurons not shut down all the 
components of the apoptotic pathway?  Mature sympathetic neurons repress Apaf-1 but 
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continue to express many apoptotic proteins including Bax, caspase-9 and caspase-3 
(Wright et al., 2007). A potential explanation for this has come from recent studies that 
have found these proteins to have functions outside of the canonical apoptotic pathway.  
For example, Bax is known to regulate mitochondrial dynamics and caspases-9 and -3 
have essential roles in synaptic plasticity and axon pruning, which are events that are 
important for optimal neuronal function and plasticity (Unsain and Barker 2015). Thus, 
maintaining these proteins, albeit with increased regulation, permits mature neurons to 
utilize these proteins while simultaneously limiting the risk of apoptosis.   
 Despite the mechanisms described here that provide neurons with improved 
capacity to survive injury and apoptosis, adult neurons can still be vulnerable and 
undergo cell death in situations of acute brain injury or neurodegenerative disease.  It is 
possible that even the partial removal of these apoptotic brakes that could occur with 
injury or chronic neurodegeneration could increase the vulnerability of adult neurons. 
Indeed, consistent with a role of miR-29 in neuroprotection, its levels are reduced in 
Alzheimer’s disease, Huntington’s disease, and during hypoxic-ischemic brain injury 
(Khanna et al., 2013; Shioya et al., 2010; Johnson et al., 2008). Restoring these brakes 
on the apoptotic pathway via overexpression of miR-29 or miR-24 could be an effective 
therapeutic strategy that promotes long-term neuroprotection.  A previous study 
reported that mice partially deleted for miR-29 (deletion of the miR-29a/b1 loci) had 
grossly normal brains but exhibited an ataxic phenotype (Papadopoulou, Serneels et al. 
2015). Our findings that apoptosis is not increased in miR-29 knockout neurons support 
the hypothesis that observed phenotypes in these  studies are more likely to be due to 
the effect of miR-29 on neuronal function rather than survival.  
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 Together, our results identify miR-29 as sufficient but not solely responsible for 
the inhibition of the apoptotic pathway in mature neurons, and highlight the redundant 
brakes employed by mature neurons to inhibit apoptosis and promote long-term 
survival. 
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2.4 Materials and Methods 
Cell Culture  
For young neurons, sympathetic ganglia were isolated and cultured from neonatal 
CD1 mice unless otherwise indicated as described previously (Potts et al., 2003). All 
animal handling and protocols were carried out in accordance with established practices 
as described in the National Institutes of Health Guide for Care and Use of Laboratory 
Animals and as approved by the Animal Care and Use Committee of the University of 
North Carolina (UNC). 
Neurons were then maintained in culture for 5 days. For mature neurons, ganglia 
from P5-P12 mice were isolated and cultured as previously described until 28-35 DIV 
(Wright et al., 2007). NGF deprivation experiments were performed by washing cells 
three times with media containing no NGF, then refeeding cells in NGF-free media 
containing NGF-neutralizing antibody. For DNA damage experiments, cells were treated 
with 20 µM Etoposide (Sigma).  For luciferase assay experiments, HEK293T cells were 
grown in DMEM/F12 medium supplemented with 10% FBS, 100u/mL penicillin, and 
100µg/mL streptomycin.  
 
RNA Isolation and RT-qPCR 
RNA was isolated from tissue or cultured cells using the Zymo Research Direct-zol 
RNA MiniPrep kit (Genesee) according to the manufacturer’s instructions. Mature 
miRNA expression was determined using hydrolysis probe based-miRNA assays 
(Taqman/Life Technologies). RT primers specific for miR-29a, miR-29b, miR-29c, miR-
24, miR-124, miR-128 and U6 were used to amplify the indicated genes from 10 ng of 
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isolated RNA using the Superscript III Reverse Transcriptase system (Life 
Technologies) according to manufacturer instructions. cDNA was amplified using 
TaqMan universal PCR master mix (Life Technologies) on an ABI 7500 Real-Time PCR 
system. Relative quantification and statistical comparisons were performed using the 
delta-delta-ct method. Samples were internally normalized to U6 SnoRNA expression. 
For non-miRNA gene expression, cDNA libraries were prepared using 50-100 ng RNA. 
RNA was pre-treated with RQ1 DNase (Promega) for 30 minutes at 37°C followed by 10 
min incubation with DNAse Stop Solution at 65°C for 10 min. cDNA was reverse-
transcribed using random hexamers (Invitrogen) and the Superscript III Reverse 
Transcriptase System according to manufacturer instructions. cDNA was diluted 1:20 in 
each qPCR reaction, along with 400 nM of forward and reverse primers and Power 
SYBR Green PCR master mix (Applied Biosystems). BH3-only gene and GAPDH 
primers have been previously published (Kole et al., 2011). Reactions were amplified in 
an ABI 7500 Real-Time PCR system. Relative quantification and statistical comparisons 
were performed using the delta-delta CT method. Samples were internally normalized to 
GAPDH expression.   
Small RNA sequencing library production and mapping 
Libraries for Illumina sequencing were prepared using a modification of the TruSeq 
protocol.  Briefly, 1 ug total RNA was ligated to 3 pmol of the 3' linker using T4 RNA 
ligase 2. RNA size fractions corresponding to 35- 70 nucleotides (insert plus linker) 
were gel isolated and ligated to 3 pmol of the 5' linker.  Products were reverse 
transcribed, PCR amplified to mid-log phase, and size isolated.  Libraries were 
barcoded using indexed 5' linkers.  Libraries were sequenced on an Illumina HiSeq 
70 
 
2000. These libraries were aligned to the mm9 genome. miRNA annotations were 
downloaded from miRBase r18.  
Immunofluorescence Staining 
 Immunofluorescence was carried out as previously described (Potts, Singh et al. 
2003). The primary antibodies used were as follows: anti-cyt c (BD Biosciences 
#556432); anti-Tom20 (Santa Cruz sc11415); anti-Bim (Cell Signaling #2189); Anti-
phospho-c-jun (Cell Signaling #9261) Secondary antibodies were anti-mouse Cy3 (The 
Jackson Laboratory) or anti-rabbit Alexa Fluor 488 (Life Technologies). Nuclei were 
stained with Hoechst 33258 (Molecular Probes). For analysis of cyt c release, neurons 
treated with apoptotic stimuli in the presence of 25 µM Q-VD-OPH to inhibit downstream 
caspase activation and preserve cells for staining. Images were acquired using an 
ORCA-ER digital B/W charge-coupled device camera (Hamamatsu) mounted to a 
DMI6000 microscope (Leica) using Metamorph 7.6 software and processed using 
Adobe Photoshop. For fluorescence intensity measurements, average pixel intensities 
were measured in individual injected neuronal cell bodies using Metamorph 7.6 
software and were normalized to neighboring uninjected cell bodies on the same plate.       
Assessment of Neuronal Survival  
Neuronal survival was assessed by the presence of intact, phase bright cell bodies 
at the indicated time after treatment. Survival was quantified as the percentage of 
healthy cells at the indicated time point compared to immediately prior to treatment. This 
method of assessing survival correlates well with independent methods of measuring 
cell death such as trypan blue exclusion and calcein AM staining (Potts et al., 2003). 
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Cloning of Puma 3’UTR and Luciferase Assays 
A 719-bp segment of the Puma 3’UTR was amplified from mouse genomic DNA 
and cloned into a modified PGL3-control plasmid (Promega), in which the multiple 
cloning site was placed downstream of the firefly luciferase gene. For luciferase assays, 
60,000 HEK293T cells were plated into each well of a 12-well plate and transfected with 
1.5 µg of PGL3-3’UTR reporter construct or empty vector, 100 ng phRL renilla luciferase 
(Promega) and 100 nM of either miR-24-3p or cel-mir-67 MIRIDIAN mimic (GE 
Dharmacon) as a negative control. Transfections were performed using lipofectamine 
2000 according to manufacturer’s instructions. 48 hours post transfection, cells were 
lysed and firefly- and renilla- luciferase intensities were measured using Promega Dual- 
Luciferase Reporter system on a Fluorscan Ascent Type 379 fluorescence plate reader 
(Thermo). Firefly luciferase intensity was normalized to renilla luciferase intensity to 
control for cell number and transfection efficiency.  
Single Cell Microinjection 
Cells were injected with Miridian mimics (GE Dharmacon) to miR-29, miR-24, miR-
124, miR-128  or cel-miR-67 as a negative control (30 uM needle concentration) or miR-
24/negative control LNAs (10uM needle concentration, Exiqon) as previously described 
(Kole et al., 2011). Briefly, mimics/LNAs were dissolved in sterile RNAse-free water and 
mixed with microinjection buffer containing 100 mM KCl and 10 mM KPi (pH 7.4) along 
with 8 mg/mL lysine-fixable Fluorescein Dextran (Invitrogen) to mark injected cells. For 
cyt c injections, 10 mg/mL of mammalian (bovine) or yeast cyt c were injected as 
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previously described (Potts et al., 2003) and cell survival was quantified by comparing 
the percentage of surviving cells immediately after injection and 24 hours post-injection. 
Generation of miR-29 knockout neurons 
To generate sympathetic neurons deficient for all three miR-29 family members, 
mice floxed at both genomic loci for miR-29 (miR-29a/b1 and miR-29b2/c)(kindly 
provided by Dr. He, Duke University) were crossed with ER-Cre (CAG-Cre/Esr1/ strain: 
004453. Jackson Laboratories). Neurons were isolated from Cre-positive and Cre-
negative littermates as previously described and treated with 500 nM 4-OH-tamoxifen 
(Sigma) for 10 days to induce recombination. Neurons were then matured until 28-35 
DIV prior to experimental treatments. Cre-positive and negative littermates were 
genotyped for Cre expression using the following primers: Forward – 
gatggacatgttcagggatcgcc. Reverse: ctcccaccgtcagtacgtgagat. Knockout of miR-29 
family expression was confirmed via RT-qPCR.  
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism Software version 5.0c. 
For comparisons between two means, unpaired student’s T-Test was used. For 
comparisons between more than two groups, one-way ANOVA with Newman-Keuls 
multiple comparisons test was used. A p-value of less than 0.05 was considered 
significant. 
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2.5 Figures and Figure Legends 
Figure 2.1: Neuronal maturation is associated with progressive resistance to neuronal 
apoptosis at both pre and post-mitochondrial checkpoints. A) Representative images of 
identical fields of 5 DIV and 11 DIV neurons imaged at 24 hour intervals after NGF deprivation. 
B) Quantification of sympathetic neuronal survival in response to NGF deprivation for 48 hours 
after maturing in culture for the indicated amount of time. Data represent mean ± SEM of 3 
independent experiments. C) Neurons isolated from neonatal XIAP-/- mice and cultured for the 
indicated time were injected with 10 mg/mL of either bovine cyt c to induce apoptosis or yeast 
cyt c as a negative control and survival was quantified 24 hours post-injection. Data are 
displayed as mean ± SEM of 3 independent experiments for 5, 10 and 15 DIV and 2 
independent experiments for 20 and 25 DIV(**=P<0.01). D) Quantification of cyt c release from 
neurons cultured for the indicated time and deprived of NGF for 48 hours (**=P<.01, 
***=P<.001). E) Representative images of cyt c and Tom20 staining in neurons matured for the 
indicated amount of time and maintained (+NGF) or deprived (-NGF) for 48 hours.  
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Figure 2.2: Mature miR-29 deficient neurons remain resistant to NGF-deprivation induced 
cyt c release. A) Timecourse of miR-29b induction in maturing neurons. Neurons were isolated 
from neonatal mice and cultured for the indicated amount of time and miR-29 levels were 
assessed by RT-qPCR. Values are expressed as mean fold change ± SEM relative to 5 DIV 
neurons from 3 independent experiments (**=p<0.01, ***=p<0.001, ns=not significant). B) 
Verification of miR-29 deficiency in mature mir-29 knockout neurons as assessed by RT-qPCR. 
Values are expressed as mean fold change ± SEM relative to WT 5 DIV neurons from 3 
independent experiments. C) Representative images of cyt c staining in mature WT and miR-29 
KO cells deprived of NGF for 48 hours. D) Quantification of cyt c release in young WT neurons 
and mature WT and mature miR-29 KO neurons deprived of NGF for 48 hours. Data represent 
the percentage of cells with mitochondrial cyt c and are presented as mean ± SEM of 3 
independent experiments.  E)  RT-qPCR quantification of selected BH3-only genes in young, 
mature WT, and mature miR-29 KO neurons deprived of NGF for 48 hours. Fold changes were 
normalized to P5 +NGF neurons and represent mean ± SEM of 3 independent experiments. 
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Figure 2.3: Other miRNAs predicted to regulate the apoptotic pathway are also induced 
with neuronal maturation.  A) Schematic showing candidate pools of miRNAs that may also 
regulate cell death in maturing neurons. B) Table of predicted targets for candidate miRNAs by 
TargetScan software. C-E) Relative expression levels of candidate miRNAs in maturing 
cerebellum.  Values are expressed relative to young (P5) cerebellum and represent mean ± 
SEM of 3 independent experiments. F-H) Relative expression levels of candidate miRNAs in 
young (5 DIV) and mature (28 DIV) sympathetic neurons measured by RT-qPCR. Values are 
expressed as fold-change relative to expression in young neurons and represent mean ± SEM 
of 3 independent experiments (*=P<0.05 **=p<0.01 ***=P<0.001, ns=not significant). 
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Figure 2.4: Overexpression of miR-29 or miR-24 is sufficient to inhibit cyt c release and 
cell death in young, NGF deprived neurons. A) Representative images of sympathetic 
neurons injected with mimics to candidate miRNAs or negative control mimic. Injected cells 
(arrows) are marked with FITC-Dextran (green) and cyt c release (red) was assessed after 48 
hours of NGF deprivation. B) Quantification of cyt c release in injected cells after 48 hours of 
NGF deprivation. Data are represented as mean ± SEM of 3 independent experiments 
(*=P<0.05, ***=P<0.001). C) Quantification of neuronal survival in neurons injected with mimics 
to miR-29, miR-24, or a negative control (ncmiR) after 48 hours of NGF deprivation. Survival is 
expressed as the percentage of cells remaining compared to the number alive pre-deprivation. 
Data represent mean ± SEM of at least 3 independent experiments. 
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Figure 2.5: Overexpression of miR-29 or miR-24 is sufficient to inhibit the induction of 
Bim and Puma in young sympathetic neurons. A) Representative images of Bim staining in 
neurons. Neurons were injected at 3 DIV with mimics to miR-29, miR-24, or a negative control, 
along with FITC-Dextran (Green) to mark injected cells. At 5 DIV neurons were deprived of NGF 
and after 48 hours of NGF deprivation, neurons were fixed and stained for Bim (red). B) 
Quantification of normalized Bim staining intensity. Bim staining intensity was measured, and 
values for injected cells were normalized to NGF-deprived, mock injected neurons. Data 
presented as mean intensity ± SEM of 3 independent experiments (*=P>0.05). C) Sequence 
and alignment of miR-24 seed sequence with two putative miR-24 target sites in Puma 3’UTR.  
D) Luciferase activity was measured 48 hours after transfection in HEK293T cells transfected 
with reporter plasmids containing the Puma 3’UTR fused to a firefly luciferase gene. Plasmids 
were transfected either alone or with 100 nM mimics of miR-24 or negative control. Expression 
was normalized by measuring the ratio of firefly to renilla luciferase. Values are plotted relative 
to vector alone and represent mean ± SEM of 3 independent experiments (*=P<0.05). E) 
Representative images of cyt c staining in neurons injected with mimics to miR-29, miR-24, or 
negative control miR (ncmiR) and treated with 20 µM etoposide. Green indicates injected cells 
(arrows). F) Quantification of cyt c release in young neurons injected with mimics to miR-29, 
miR-24, or negative control after 48 hours of etoposide treatment. Data are plotted as mean ± 
SEM of 3 independent experiments (***=P<0.001). 
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Figure 2.6: Inhibition of miR-24 Function in miR-29 Knockout Neurons Leads to 
Partial Restoration of Apoptotic Response A) Images of mature miR-29 knockout 
neurons microinjected with negative control LNA (ncLNA) or miR-24 LNA along with 
FITC dextran to mark injected cells. Neurons were deprived of NGF 48 hours post-
injection and fixed for immunofluorescence 96 hours later. B) Quantification of the 
percentage of injected cells described in (A) with cyt c maintained at the mitochondria, 
presented as mean ±SEM of 3 independent experiments (*=P<.05). C) Representative 
images of young (5DIV) and mature (28DIV) neuronal cultures deprived of NGF for 48 
hours and stained for phospo-c-jun (P-C-Jun). Dapi staining indicates nuclei. D) 
Quantification of the percentage of young (5 DIV) and mature (28 DIV) neurons 
expressing nuclear phospho-c-jun 48 hours post-NGF deprivation, presented as mean 
±NGF of 2 independent experiments. 
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Table 2.1 Small-RNA-Seq Results from Maturing Cerebellum 
Results of small-RNA-Seq on developing cerebellum. Data are shown as log(2) of the 
Fold-Change comparing P2 and P250 Cerebellum. 
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Table 2.1: Small-RNA-Seq Results from Maturing Cerebellum 
miRNA 
Log(2) Fold 
change 
mmu-mir-29a-3p_-_1 9.23922243 
mmu-mir-29b-1-3p 8.546476048 
mmu-mir-29a-3p 8.418622901 
mmu-mir-29b-2-3p 8.262343047 
mmu-mir-29c-3p 6.112164983 
mmu-mir-129-1-3p 4.249326455 
mmu-mir-219-2-3p 4.192633704 
mmu-mir-129-2-3p 3.914220479 
mmu-mir-222-3p 3.442700429 
mmu-mir-24-2-3p 3.377987339 
mmu-mir-24-1-3p 3.377971596 
mmu-mir-26a-2-5p_-
_2 3.341914749 
mmu-mir-128-2-3p_-
_1 3.327847744 
mmu-mir-137-3p 3.288597694 
mmu-mir-1a-1-3p 3.047960954 
mmu-mir-1a-2-3p 3.047960954 
mmu-mir-128-1-3p_-
_1 2.940839678 
mmu-mir-128-1-3p 2.686971342 
mmu-mir-128-2-3p 2.631897785 
mmu-let-7i-5p_-_1 2.519435807 
mmu-mir-153-3p 2.489955637 
mmu-mir-22-3p 2.474592691 
mmu-mir-124-3-3p_-
_2 2.448247613 
mmu-mir-124-2-3p_-
_2 2.448247613 
mmu-mir-124-1-3p_-
_2 2.448247613 
mmu-mir-34a-5p 2.282094191 
mmu-mir-378-3p 2.12741106 
mmu-mir-26a-2-5p_-
_1 1.924286049 
mmu-mir-218-2-5p 1.85367829 
mmu-mir-137-3p_+_2 1.843588197 
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mmu-mir-218-1-5p 1.840203945 
mmu-mir-143-3p 1.734142813 
mmu-mir-127-3p 1.650469282 
mmu-mir-136-5p 1.622172823 
mmu-let-7g-5p_-_1 1.466853075 
mmu-let-7g-5p_+_1 1.454552294 
mmu-mir-137-3p_+_1 1.433874345 
mmu-mir-23b-3p 1.430342439 
mmu-let-7a-1-5p_-_1 1.366081503 
mmu-mir-124-2-3p_-
_1 1.314951681 
mmu-mir-124-3-3p_-
_1 1.314951681 
mmu-mir-124-1-3p_-
_1 1.311127769 
mmu-mir-708-5p 1.30052708 
mmu-mir-27b-3p 1.298943716 
mmu-mir-411-5p_-_1 1.261353347 
mmu-let-7b-5p_-_1 1.24969777 
mmu-let-7c-2-5p_-_1 1.207648719 
mmu-let-7f-2-5p_-_2 1.148975632 
mmu-mir-26a-1-5p 1.124395481 
mmu-mir-26a-2-5p 1.124300226 
mmu-let-7g-5p 1.005429898 
mmu-mir-26b-5p_-_1 0.976860419 
mmu-mir-138-1-5p 0.896873914 
mmu-mir-23a-3p 0.893842957 
mmu-mir-124-3-
3p_+_1 0.855112228 
mmu-mir-124-1-
3p_+_1 0.855112228 
mmu-mir-124-2-
3p_+_1 0.855112228 
mmu-mir-191-5p 0.855015503 
mmu-mir-124-2-3p 0.853413745 
mmu-mir-124-3-3p 0.853308973 
mmu-mir-124-1-3p 0.852844885 
mmu-let-7d-5p_-_1 0.82206245 
mmu-mir-101b-3p_-_1 0.817807326 
mmu-mir-185-5p 0.816348799 
mmu-let-7c-1-5p_-_1 0.755457368 
89 
 
mmu-mir-101a-3p_-_1 0.700314298 
mmu-mir-26a-1-5p_-
_1 0.616025135 
mmu-mir-379-5p 0.55574293 
mmu-mir-27a-3p 0.497080758 
mmu-mir-7b-5p 0.458406739 
mmu-mir-369-3p 0.425925906 
mmu-mir-195-5p_-_1 0.408782549 
mmu-mir-101b-3p 0.331923495 
mmu-let-7a-1-5p_-_2 0.261049517 
mmu-mir-335-5p_-_1 0.158111653 
mmu-let-7f-2-5p_-_1 0.089385292 
mmu-mir-30a-5p 0.052439317 
mmu-mir-497-5p 0.041892357 
mmu-mir-126-5p 0.028607886 
mmu-mir-381-3p 0.018924586 
mmu-mir-434-3p -0.026370409 
mmu-mir-376a-3p -0.058299236 
mmu-mir-495-3p_+_1 -0.073196717 
mmu-mir-384-5p -0.161129262 
mmu-mir-99a-5p_-_1 -0.161624895 
mmu-mir-382-5p -0.239536221 
mmu-mir-425-5p -0.24008956 
mmu-let-7f-1-5p_-_2 -0.257280982 
mmu-mir-411-3p -0.264921938 
mmu-let-7a-2-5p_-_1 -0.275268004 
mmu-mir-376b-3p -0.276588251 
mmu-mir-125a-5p -0.310052225 
mmu-mir-30e-5p -0.354308275 
mmu-let-7d-5p -0.36935894 
mmu-mir-21-5p -0.400232233 
mmu-mir-98-5p -0.487055185 
mmu-mir-495-3p -0.502532628 
mmu-mir-1839-5p -0.518157362 
mmu-mir-30d-5p -0.524083907 
mmu-mir-451 -0.570611839 
mmu-mir-335-5p_+_2 -0.611990948 
mmu-let-7e-5p_-_1 -0.628569476 
mmu-mir-195-5p -0.647371312 
mmu-let-7b-5p -0.669297337 
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mmu-mir-30c-1-5p -0.679881901 
mmu-mir-30c-2-5p -0.680165226 
mmu-mir-369-5p -0.700810046 
mmu-mir-181a-2-5p_-
_1 -0.704041701 
mmu-mir-181a-1-5p_-
_1 -0.704041701 
mmu-let-7c-1-5p -0.731466983 
mmu-let-7c-2-5p -0.732192919 
mmu-mir-99a-5p -0.736326745 
mmu-mir-335-5p -0.773092289 
mmu-mir-9-2-5p -0.78268716 
mmu-mir-9-3-5p -0.783846295 
mmu-mir-9-1-5p -0.783867545 
mmu-let-7i-5p -0.785982446 
mmu-mir-126-3p_+_1 -0.794012263 
mmu-mir-103-1-3p -0.809430894 
mmu-mir-181a-2-5p -0.810391646 
mmu-mir-181a-1-5p -0.811034165 
mmu-mir-598-3p -0.812108815 
mmu-mir-26b-5p -0.835977758 
mmu-mir-103-2-3p -0.853980791 
mmu-mir-9-2-5p_-_1 -0.855803649 
mmu-mir-9-1-5p_-_1 -0.857053818 
mmu-mir-126-3p -0.858490757 
mmu-mir-140-3p_+_1 -0.93067046 
mmu-let-7a-2-5p -0.949281846 
mmu-let-7a-1-5p -0.955962468 
mmu-let-7f-1-5p_-_1 -1.000851592 
mmu-mir-361-5p -1.003216283 
mmu-mir-194-2-5p -1.010806118 
mmu-mir-30b-5p -1.023988091 
mmu-let-7f-2-5p -1.024257168 
mmu-mir-543-3p -1.029183671 
mmu-let-7f-1-5p -1.036474067 
mmu-mir-300-3p -1.056206471 
mmu-let-7e-5p -1.100715724 
mmu-let-7c-2-5p_+_1 -1.134077728 
mmu-let-7c-1-5p_+_1 -1.134077728 
mmu-mir-151-5p -1.145683351 
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mmu-mir-9-3-3p_+_2 -1.15518218 
mmu-mir-181b-1-5p -1.175644356 
mmu-mir-744-5p -1.203349171 
mmu-mir-9-2-3p_+_2 -1.246505021 
mmu-mir-9-1-3p_+_2 -1.246505021 
mmu-mir-7a-2-5p -1.265238736 
mmu-mir-7a-1-5p -1.284369518 
mmu-mir-125b-2-5p_-
_1 -1.288522613 
mmu-mir-125b-1-5p_-
_1 -1.288522613 
mmu-mir-9-1-5p_+_1 -1.315373304 
mmu-mir-9-3-5p_+_1 -1.315373304 
mmu-mir-9-2-5p_+_1 -1.316513399 
mmu-mir-101a-3p -1.318459897 
mmu-mir-320-3p -1.337016292 
mmu-mir-9-2-3p_-_1 -1.337780279 
mmu-mir-9-1-3p_-_1 -1.337780279 
mmu-mir-9-3-3p_-_1 -1.352835029 
mmu-mir-106b-5p_-_2 -1.359808157 
mmu-mir-872-5p -1.404430399 
mmu-mir-107-3p -1.419890057 
mmu-mir-16-1-5p_-_1 -1.439861708 
mmu-mir-411-5p -1.441712221 
mmu-mir-181b-2-5p -1.447897426 
mmu-mir-382-3p_-_2 -1.448765918 
mmu-mir-16-2-5p_-_1 -1.468414749 
mmu-mir-376c-3p -1.525993473 
mmu-mir-9-3-3p -1.56085854 
mmu-mir-9-2-3p -1.566574733 
mmu-mir-9-1-3p -1.566580575 
mmu-mir-186-5p -1.646720015 
mmu-mir-9-2-5p_-_2 -1.675309982 
mmu-mir-9-1-5p_-_2 -1.675309982 
mmu-mir-125b-2-5p -1.736121068 
mmu-mir-125b-1-5p -1.758028164 
mmu-mir-149-5p -1.823304344 
mmu-mir-374-5p -1.844414727 
mmu-mir-16-2-5p -1.87960219 
mmu-mir-16-1-5p -1.885232943 
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mmu-mir-100-5p -1.979151008 
mmu-mir-92b-3p -2.009621802 
mmu-mir-34c-5p -2.018246702 
mmu-mir-152-3p -2.059913093 
mmu-mir-181c-5p -2.073628414 
mmu-mir-148b-3p -2.133364514 
mmu-mir-410-3p -2.226426994 
mmu-mir-99b-5p -2.237806201 
mmu-mir-487b-3p -2.244155221 
mmu-mir-342-3p -2.351102694 
mmu-mir-9-1-3p_+_1 -2.392679844 
mmu-mir-9-2-3p_+_1 -2.392685836 
mmu-mir-154-3p -2.428520907 
mmu-mir-652-3p -2.439450885 
mmu-mir-9-3-3p_+_1 -2.468227216 
mmu-mir-127-5p_+_2 -2.470743612 
mmu-mir-33-5p -2.580869801 
mmu-mir-421-3p -2.58301589 
mmu-mir-323-3p -2.638004791 
mmu-mir-181d-5p -2.797523715 
mmu-mir-135b-5p -3.018604366 
mmu-mir-15a-5p -3.049165869 
mmu-mir-340-5p_-_1 -3.201506566 
mmu-mir-322-5p_-_1 -3.202972067 
mmu-mir-204-5p -3.291480082 
mmu-mir-423-3p -3.294485572 
mmu-mir-340-5p -3.396245583 
mmu-mir-322-5p -3.506050923 
mmu-mir-350-3p -3.569090388 
mmu-let-7d-3p -3.57574818 
mmu-mir-135a-2-5p -3.893240357 
mmu-mir-135a-1-5p -3.932005901 
mmu-mir-106b-5p_-_1 -4.136345487 
mmu-mir-484 -4.287377713 
mmu-mir-25-3p -4.471453512 
mmu-mir-301a-3p -4.689092404 
mmu-mir-17-3p -4.78722938 
mmu-mir-106b-5p -4.994931598 
mmu-mir-93-5p -5.069107244 
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mmu-mir-206-3p -5.183435471 
mmu-mir-92a-1-3p -5.461448418 
mmu-mir-449a-5p -6.355656513 
mmu-mir-15b-5p -6.676286846 
mmu-mir-18a-5p -6.750281879 
mmu-mir-130a-3p -6.895129855 
mmu-mir-17-5p -7.038792003 
mmu-mir-20a-5p -7.066782902 
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CHAPTER 3: SPATIAL AND TEMPORAL REGULATION OF BAX ACTIVATION IN 
NEURONS 
 
3.1 Introduction 
 The Bax/Bak mediated release of cyt. c from the mitochondria is the most 
important event in the execution of the intrinsic apoptotic pathway. Inhibition of 
apoptosis by Bax and Bak deletion in mice leads to perinatal lethality in ~90% of 
offspring. Mice that do survive past the perinatal period exhibit widespread defects, 
including persistant interdigital webs, imperforate vaginal canals in females, and excess 
cells present in both the nervous and hematopoietic systems (Lindsten et al., 2000).  
 As described in the introduction, the activation of Bax/Bak is governed by the 
BCL-2 family of proteins. The pro-apoptotic members of the BCL-2 family, known 
collectively as the BH3-only domain proteins, have been found to regulate Bax 
activation. Individual knockouts of various BH3-only genes in mice have revealed 
varying and often overlapping contributions to apoptosis that vary with tissue type and 
apoptotic stimulus. Among the BH3-only genes that play a role in neuronal cell death, 
systemic knockout of Bim leads to hyperplasia of lymphoid and myeloid cells, increased 
resistance of many cell types to cytokine deprivation, and slightly increased resistance 
of some cell types to DNA damage (Bouillet, Metcalf et al. 1999). Mice lacking Puma 
expression display widespread cellular resistance to DNA damage, underscoring the 
role that Puma plays in P53-dependent cell death (Villunger, Michalak et al. 2003). 
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Genetic deletion of HRK leads to only mild resistance of certain neuronal populations to 
apoptosis induced by nerve growth factor deprivation of axotomy (Imaizumi, Benito et 
al. 2004; Coultas, Terzano et al. 2007). 
 The reason for the varying phenotypes of BH3-only gene knockout mice is due in 
part to differences in gene expression (e.g. Hrk is thought to be a neuronal specific 
BH3-only gene), but also due to varying binding affinities for other members of the BCL-
2 family, with whom BH3-only proteins interact extensively. The interactions of the BH3-
only domain proteins with other members of the BCL-2 family has been intensively 
studied using yeast two-hybrid analyses, plasmon-resonance binding assays and cell 
free liposome/mitochondrial permeablization assays (Youle and Strasser 2008). This 
has led to the grouping of the BH3-only genes into two subgroups: activators, which 
include Bim, Bid, and probably Puma, are distinguished by their ability to directly 
interact with Bax and/or Bak (Letai, Bassik et al. 2002; Kuwana, Bouchier-Hayes et al. 
2005; Kim, Tu et al. 2009). Sensitizers, which comprise the remaining members of the 
BH3-only domain proteins, fail to interact directly with Bax but interact with and inhibit 
pro-survival members of the BCL-2 family, preventing them from inhibiting the activation 
of Bax. This sub-grouping of pro-death proteins has coincided with the rise of two 
different, though not mutually exclusive, models of apoptosis: the indirect and direct 
activation models. 
 In the indirect activation model, a subpopulation of Bax is “primed” for apoptosis, 
or even constitutively active, and must be constantly restrained by pro-survival BCL-2 
members (BCL-2, BCL-XL, BCL-W, and MCL-1). This model is supported by the finding 
that HEK cells lacking Bim and Bid and with Puma knocked down by siRNA were still 
96 
 
able to activate Bax and undergo apoptosis when pro-survival BCL-2 members were 
exogenously inhibited by drugs or overexpression of sensitizer proteins (Willis, Fletcher 
et al. 2007). Intriguingly, it was recently reported that a subset of Bax in healthy cells 
spontaneously activates and translocates to the mitochondria, and is continuously 
shuttled back to the cytoplasm in a BCL-XL dependent manner (Edlich, Banerjee et al. 
2011). Under these circumstances, inhibition of BCL-XL may impair the 
retrotranslocation of active Bax from the mitochondria to the cytosol, leading to Bax 
accumulation and cyt c release. This hypothesis is also supported by experiments with 
Bax mutants that abolish its interaction with pro-survival BCL-2 family members, which 
lead to constitutive apoptosis (Fletcher, Meusburger et al. 2008; Czabotar, Lessene et 
al. 2014).  
 In the direct activation model, Bax activation and cyt c release are dependent on 
the interaction with the direct activator BH3-only proteins Bid, Bim, and/or Puma. While 
many lines of evidence for this model exist, the most definitive evidence was provided 
by the creation of Bid/Bim/Puma triple-deficient mice. These mice, which lack 
expression of all known direct activators, but maintain expression of sensitizer BH3-only 
proteins, were found to recapitulate many of the phenotypes of the Bax/Bak double 
knockout mice. While Bid/Bim/Puma triple-knockout did not have as profound an effect 
on perinatal survival as double deletion of Bax and Bak, surviving Bid/Bim/Puma 
knockouts displayed many of the same developmental abnormalities, including 
persistant interdigital webbing, imperforate vaginal canals, and accumulation of 
hematopoietic cells. Bid/Bim/Puma triple-knockout cerebellar granule neurons also 
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displayed marked resistance to ionizing radiation and potassium deprivation (Ren et al., 
2010).  
 These two models of cell death are not mutually exclusive and can be difficult to 
distinguish from one another. It is likely that different cell types have different activation 
thresholds for apoptosis. In some cell types, Bax may be “primed” in such a way that 
simply removing the anti-apoptotic brakes allows apoptosis to proceed, while in others, 
apoptosis may be restricted to such an extent that activation of both activators and 
sensitizers is required for proper execution of apoptosis.  
 A method that has emerged recently for measuring the threshold for apoptosis in 
different cell types is known as BH3-profiling. BH3 profiling is performed by subjecting 
either isolated mitochondria or permeablized cells from different cell lines or patients to 
treatment with purified BH3-only domain peptides and measuring the degree of 
mitochondrial permeablization and/or cyt c release that results (Del Gaizo Moore and 
Letai 2012).  
 Other tools that can be used to explore the apoptotic threshold in different cell 
types are small-molecule mimetics of BH3-only genes. The first of these, ABT-737, was 
discovered in 2005 and remains widely used (Oltersdorf, Elmore et al. 2005). An orally 
bioavailable version of ABT-737, ABT-263, is currently in clinical trials as a 
chemotherapeutic agent under the trade name Navitoclax, along with a related 
compound, Obatoclax. ABT-737 is known to act by inhibiting the anti-apoptotic BCL-2 
family members BCL-2, BCL-XL, and BCL-W. In cancer cells that overexpress one of 
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these proteins, treatment with ABT-737 can sensitize the cells to chemotherapeutic 
drugs.  
 While extensive studies have been conducted using these tools in cancer cells 
and immortalized cell lines, there are few studies that have made use of them to study 
the regulation of apoptosis in primary cells like neurons. Neurons make for an especially 
interesting system in which to utilize these tools for two reasons: first, as has already 
been described in this dissertation, neurons dynamically regulate apoptosis as they 
mature; and second, neurons are the most highly spatially specialized cells in the body. 
 When studying the temporal regulation of apoptosis in neurons, we have focused 
on downregulation of certain pro-apoptotic genes, such as Apaf-1, and restriction of 
BH3-only gene induction by microRNAs. However, other possibilities for the regulation 
of apoptosis exist. Namely, while the expression of Bax does not change in maturing 
sympathetic neurons, it is not clear whether there may be modifications of Bax that 
change its threshold for activation. BH3-profiling and treatment with BH3-mimetic drugs 
provide tools that allow more direct assessment of Bax activation in neurons, and how 
its activation threshold may be modulated in maturing neurons independent of miRNAs 
or BH3-transcription.  
 
Spatial Regulation of Apoptosis in Neurons 
 The spatial localization of apoptosis in neurons is a field of study that has 
exploded in the past 8 years, beginning with the publication of the finding that neurons 
subjected to local deprivation of growth factors employ a specialized pathway to prune 
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or destroy axons while sparing the cell body. Unlike whole-neuron apoptosis, axon 
pruning is dependent on activation of Caspase 6, which is not required for whole-neuron 
apoptosis (Nikolaev, McLaughlin et al. 2009; Cusack, Swahari et al. 2013). In order to 
locally deprive axons while leaving somas in the presence of growth factor, 
compartmented culture systems such as microfluidic or campenot chambers are 
employed. These chambers place barriers between the soma and axon compartments, 
allowing independent treatment of each subcellular compartment.  
 Since the first study implicating Caspase 6, many aspects of this dedicated axon 
pruning pathway have become clearer. Loss of TRKA signaling in the axons leads to a 
DLK-dependent retrograde signal being transmitted to the soma (Simon, Pitts et al. 
2016). Activation of DLK leads to local phosphorylation of JNKs, which are required for 
axon pruning to take place (Ghosh, Wang et al. 2011). Similar to whole-cell apoptosis, 
c-jun is phosphorylated and translocates to the nucleus when axons are locally deprived 
of NGF, although it is unclear whether c-jun activation is required for the execution of 
the axon degeneration program (Mok, Lund et al. 2009; Ghosh, Wang et al. 2011). Axon 
pruning has also been found to require the presence of Bax, Caspase-9, and Caspase-
3 (Nikolaev, McLaughlin et al. 2009; Schoenmann, Assa-Kunik et al. 2010; Cusack, 
Swahari et al. 2013). Knockout of any of those three genes renders axons resistant to 
local-deprivation induced pruning, although interestingly, knockout of Apaf-1, a gene 
which is required for the execution of whole cell apoptosis, was not found to inhibit local-
deprivation induced axon pruning. Consistent with this, mature neurons, which are 
known to downregulate Apaf-1 to restrict the apoptotic pathway, maintain their ability to 
locally activate apoptosis for the purpose of axon pruning (Cusack et al., 2013). 
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 These findings, that neurons can locally activate the apoptotic machinery for the 
purposes of axon pruning, and that mature neurons maintain this ability despite 
restricting apoptosis in the context of whole-cell growth factor deprivation, raise many 
interesting questions. Chief among these questions is how neurons maintain a 
permissive environment for apoptosis in axons while restricting it in somas. To examine 
this further, we have examined the effects of small molecule BH3-mimetics as well as 
purified BH3-peptides on the neuronal apoptotic pathway. 
 
3.2: Materials and Methods 
Cell Culture and Drug Treatments 
Neurons were isolated from neonatal (P0/P1) sympathetic neurons as previously 
described (Potts et al., 2003). ABT-737 (Selleckchem) was used at a final concentration 
of 10µM. NGF deprivation was conducted as described in Chapter 2. For mature neuron 
experiments, neurons were maintained in culture until P28-equivalent prior to 
treatments. For cell permeablization experiments, Digitonin (Promega) was added to 
cells for the indicated time period at the indicated concentrations.  
 
Immunofluorescence 
Immunofluorescence for cyt c and Tom20 was conducted as described in Chapter 2. 
Propidium Iodide (Sigma) was applied to cells at 2.5ug/mL.  
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Image Acqusition 
Images were acquired and processed as described in Chapter 2. 
 
Western Blot 
Western blots were performed as described in Potts et al., 2003. Primary antibodies 
used for western blot were anti-cytochrome c (BD Pharmingen 556433, 1:500 Dilution), 
anti-Bim (Cell Signaling, 2819, 1:1000 Dilution), anti-alpha-tubulin (Sigma, 1:10000 
Dilution) 
Single-Cell Microinjection 
Microinjection solutions were made as described in Chapter 2. For BH3 peptide 
injections, purified BH3-only domain peptides for Bim (Anaspec), BMF (Genscript) and 
Puma (Genscript) were dissolved in 33% DMSO and injected into sympathetic neurons 
as described above at a concentration of .6mg/mL (Bim) or 12mg/mL (BMF, Puma). 
Neurons were fixed 24 hours post-injection and the status of cyt c was assessed using 
immunofluorescence.  
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3.3 Results 
Treatment with ABT-737 Causes Selective Degeneration of Axons in Young Neurons 
 To explore the apoptotic “priming” status of neurons, we treated young neurons 
with the small-molecule BH3-mimetic drug ABT-737. ABT-737 is a small molecule 
designed to mimic the effects of the BH3-protein Bad, and binds to the pro-survival 
BCL-2 family members BCL-2, BCL-XL, and BCL-W, inhibiting their activity. We find 
that upon treatment with ABT-737 for 48 hours, sympathetic neurons exhibit extensive 
axon beading that resembles the axon degeneration observed in sympathetic neurons 
locally deprived of NGF (Figure 3.1 B,D, F). Interestingly, the cell bodies of these 
neurons fail to exhibit the characteristic condensation and degeneration associated with 
apoptosis (Figure 3.1 A, C, E).  
 
ABT-737 Induces Global Cytochrome c Release in Young Sympathetic Neurons 
 Immunostaining experiments revealed that treatment with ABT-737 in young 
neurons induced the release of cyt c from the mitochondria in both the somas and 
axons (Figure 3.2 A). This observation is not inconsistent with the previous observation 
that axons of young ABT-737-treated neurons degenerate while Somas do not. It has 
previously been found that the proper execution of neuronal apoptosis requires the 
development of so-called “competence to die”. In experiments that simulate the release 
of cyt c from mitochondria by injecting purified exogenous cyt c directly into the cytosol, 
it was found that neurons were remarkably resistant to death induced by cyt c injection 
as long as they were maintained in NGF. If neurons were deprived of NGF but saved by 
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the addition of the protein synthesis inhibitor cycloheximide, they maintained their own 
cyt c at the mitochondria, but underwent robust apoptosis in response to cyt c injection 
(Deshmukh and Johnson 1998). The development of competence to die was later found 
to involve the degradation of the inhibitor of apoptosis XIAP. Neurons cultured from 
XIAP -/- animals undergo apoptosis in response to cyt. c injection in the presence of 
NGF (Potts et al., 2003). Thus, the failure of neuronal somas to degenerate after ABT-
737 induced cyt c release may reflect inhibition of active caspases by XIAP. 
Interestingly, XIAP was recently found to be present in axons, and loss of XIAP 
expression lead to accelerated axon degeneration (Unsain, Higgins et al. 2013). Axons 
treated with ABT-737 may degenerate because XIAP is differently regulated/enriched or 
more easily overwhelmed in axons compared with somas. This result was also 
surprising because it suggested that neurons were more primed than expected to 
release cyt c, since inhibition of apoptotic brakes with ABT-737 was sufficient to induce 
the release of cyt c on its own.  
 
ABT-737 Induces Axon-Specific Cytochrome c Release in Mature Neurons 
 Since mature neurons are well known to be more resistant to cyt c release and 
apoptosis than young neurons, we next tested the response of mature neurons to 
treatment with ABT-737. Consistent with our previous findings that mature neurons are 
more resistant to apoptosis than young neurons, mature neurons failed to release cyt c 
from mitochondria in their somas in response to ABT-737. In contrast, mature neuron 
axons still exhibited robust cyt c release in response to ABT-737 treatment (Figure 3.2 
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B). This result is consistent with the previously published finding from our lab that 
mature neurons subjected to local deprivation of NGF were still able to degenerate their 
axons, while mature neurons globally deprived of NGF did not degenerate either axons 
or somas (Cusack et al., 2013). This also suggests that apoptotic brakes are 
differentially regulated within mature neurons, and that mature neurons maintain a 
permissive environment for apoptosis in their axons while restricting the apoptotic 
pathway in their somas. This finding may be partially explained by recently published 
findings from another lab that explored the subcellular distribution of apoptotic brakes. It 
was found that BCL-W -/- mice exhibited a progressive sensory neuropathy that 
exhibited manifested as decreased axonal innervation of the epidermis, but that cell-
bodies of the innervating neurons were unaffected, suggesting that loss of BCL-W led to 
an axon-specific degeneration phenotype. BCL-W was found to be enriched in axons 
compared to BCL-2 and BCL-xl, and BCL-W -/- neurons exhibited defects in axonal 
mitochondrial morphology and function (Courchesne, Karch et al. 2011). Degeneration 
of mature neuron axons in response to ABT-737 may therefore be due to inhibition of 
axonal BCL-W. However, the concentration of ABT-737 employed should be sufficient 
to overwhelm all present apoptotic brakes, so it would be surprising if differential 
distribution of BCL-W alone explained the observed degeneration. 
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NGF Deprivation Sensitizes Mature Neuron Somas to ABT-737-Induced 
Cytochrome c Release  
 As discussed above, sensitivity of neurons to cytosolic cyt c injection is governed 
by the development of competence to die, where NGF deprivation sensitizes neurons to 
death induced by purified cytochrome c. It has not yet been tested whether a similar 
phenomenon exists in neurons pre-mitochondrially. To examine this question, we paired 
ABT-737 stimulation with NGF deprivation. Neurons were deprived of NGF for 24 hours 
prior to the addition of ABT-737, and maintained in the absence of NGF during 
treatment. To our surprise, we found that deprivation of NGF was able to sensitize 
mature neurons to ABT-737, resulting in robust cyt c release (Figure 3.2 C). We 
quantified the release of cyt c from the mitochondria of young and mature neurons 
subjected to the treatments described above using immunofluorescence (Figure 3.2 D), 
and further confirmed these findings by comparing the levels of cyt c in these neurons 
using Western Blot (Figure 3.2 E). Loss of the neuronal cyt c signal in 
immunofluorescence or western blot experiments was interpreted in these experiments 
as being indicative of cyt c release, as neurons have been found to degrade the majority 
of released cyt c in response to apoptotic stimuli (Gama et al., 2014).   
 To determine if the sensitization of mature neurons to NGF-deprivation requires 
new protein transcription or translation, possibly due to limited induction of BH3-only 
domain proteins, we added the drugs actinomycin D (actin D) or cyclohexmide (CHX) 
during the 24-hour NGF deprivation pre-treatment (Figure 3.2 F). We find that CHX and 
actin D have no effect on the sensitization of mature neurons to ABT-737, suggesting 
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that this sensitization is perhaps due to loss of a pro-survival signal from NGF, rather 
than the induction of a positive pro-death signal.     
ABT-737 Treatment Results in Elevated Bim Levels in Young, but not Mature 
Neurons 
 Due to the unexpected finding that ABT-737 can induce robust cyt c release in 
young neurons, suggesting that the apoptotic pathway is more primed in young neurons 
than anticipated, we ran experiments to ensure that ABT-737 was acting as intended. If 
ABT-737 was acting solely by inhibiting apoptotic brakes, simultaneous addition of a 
translation inhibitor would be expected to have no effect on the ability of ABT-737 to 
induce cyt c release. However, when we treated sympathetic neurons with a 
combination of ABT-737 and CHX simultaneously, we found that cyt c release was 
substantially decreased in the ABT-737/CHX treated cells when compared to the cells 
treated with ABT-737 alone (Figure 3.3 A). Western blot analysis of ABT-737 treated 
neuron lysates showed that ABT-737 unexpectedly led to an increase in the levels of 
the pro-apoptotic protein Bim, which acts as a direct activator of Bax, confounding the 
results of the ABT-737 experiments (Figure 3.3 B). Interestingly, however, preliminary 
experiments suggest that treatment with CHX does not prevent the axon degeneration 
caused by ABT-737 (Figure 3.3 C). It is also noteworthy that ABT-737 is able to 
sensitize mature neurons to release cyt c in the presence of NGF, in spite of the fact 
that no elevation of Bim was detected in mature neurons in the +ABT/-NGF condition. 
 Although ABT-737 is a widely used drug in the field of apoptosis research, the 
possibility for off-target effects of ABT-737 treatment has rarely been explored. One 
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study in 2012 reported that application of ABT-737 to HeLa cells resulted in increased 
Bim levels, and that this increase in Bim occurred in a JNK-dependent manner. While 
this may further enhance the efficacy of ABT-737 as a cancer therapeutic, it negatively 
impacts our ability to use this compound as a tool to explore the regulation of the 
apoptotic pathway, since the entire reason to use it was to remove the anti-apoptotic 
proteins without affecting the pro-apoptotic genes. That said, there are several findings 
from these experiments that remain interesting and merit further explanation in spite of 
the confounds introduced by ABT-737-induced elevation of Bim levels. The fact that 
CHX cotreatment with ABT-737 did not prevent axon degeneration suggests that the 
threshold for Bax activation may indeed be different in somas and axons. The case for 
differential regulation of Bax in axons is further strengthened by the observation that 
axons in mature neurons still degenerate in response to ABT-737 treatment, and that 
ABT-737 does not induce Bim accumulation in mature neurons. Furthermore, the 
sensitization of mature neurons to ABT-737-induced cyt c release does not require 
protein synthesis, and neurons sensitized by NGF deprivation do not display increased 
Bim levels. In order to test these hypotheses properly, we have decided to explore 
alternative approaches that do not require the use of small-molecule BCL-2 family 
inhibitors.  
Direct Stimulation of Bax with BH3-Peptides as an Alternative Approach to 
Explore Bax Activation in Neurons 
 Due to the unforeseen complications arising from off-target effects of ABT-737 
treatment, an alternative approach is required to properly assess the spatial and 
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developmental regulation of Bax activation in neurons. To this end, we have pursued 
methods for directly stimulating Bax activation with purified BH3 peptides. 
 Direct stimulation of the apoptotic pathway with purified BH3 peptides is an 
approach that has become increasingly popular in the study of cancer cell apoptosis in 
the past decade (Letai, Bassik et al. 2002; Del Gaizo Moore and Letai 2012). BH3 
peptides are used instead of full-length purified proteins because BH3 proteins have 
intrinsically disordered and transmembrane domains that complicate protein purification 
efforts. Purified proteins also allow more precise control over dosage levels and can 
circumvent issues with transfection of different cells when compared to plasmid based 
overexpression studies.  
 To validate the activity of BH3 peptides in neurons, we injected young and 
mature neurons with a pool of peptides comprising the BH3 domains of Bim, Puma, and 
BMF, which are three of the four BH3-only family members that have been found to be 
upregulated in neurons undergoing apoptosis (Kristiansen et al., 2011). Notably, while 
HRK-BH3 was not available at the time these experiments were initially conducted, it 
has become available recently and will be included in future experiments. Injection of 
pooled Bim, BMF, and Puma was sufficient to induce cyt c release (assessed by 
immunofluorescence) in the majority of injected young sympathetic neurons (Figure 3.6 
A, top panels). Interestingly, mature sympathetic neurons injected with the same 
combination of peptides at the same concentration displayed markedly less cyt c 
release compared to young neurons (Figure 3.6 A, bottom panels, Figure 3.6 B). These 
results suggest that there is indeed another brake in mature neurons at the level of Bax 
mediated cyt c release. The precise nature of this brake is currently unknown, but Bax 
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activation has been found to be regulated by post-translational modifications such as 
phosphorylation, and more recently, by the formation of autoinhibitory Bax dimers 
(Gardai, Hildeman et al. 2004; Kim, Ryu et al. 2006; Quast, Berger et al. 2013; Garner, 
Reyna et al. 2016). It is possible that differences in Bax posttranslational modification or 
dimerization between young and mature neurons lead to differences in Bax sensitivity 
between young and mature neurons. 
  A limitation of this microinjection-based approach is that the effect of soma-
injected peptides on axons is difficult to properly discern. Peptides are introduced 
directly in the soma of the neurons, and it is unclear if the peptides can get into the 
axons in sufficient concentrations to have an effect by passive diffusion. Additionally, 
the status of cyt c in the axons of individual injected neurons is difficult to determine 
because of tendency of sympathetic axons in culture to form large fasciculated bundles, 
which makes it difficult to discern one axon from another within a given bundle. 
 Recent advances in BH3 profiling provide a potential solution to the limitations of 
the single-cell microinjection based approach. Early experiments in BH3 profiling were 
performed on purified mitochondria isolated from cell lines. These experiments are 
difficult to perform in primary neurons due to difficulties in obtaining sufficient material 
from cultured neurons, and obtaining axonal mitochondria specifically to explore the 
spatial aspects of apoptosis regulation would be even more difficult. However, 
techniques have recently been developed to perform BH3 profiling on adherent cells 
without having to purify intact mitochondria. Using low concentrations of the detergent 
digitonin, the cellular membrane can be permeablized while leaving the mitochondrial 
membrane intact. This allows the bath application of BH3-peptides in adherent cells, 
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using either cyt c status or mitochondrial membrane potential as a read out of Bax 
activity (Ryan and Letai 2013).  
 BH3-profiling on adherent cells is an attractive complement to single-cell 
microinjection experiments, because it would allow for the stimulation of Bax activation 
in larger populations of cells and permit analysis of differential Bax activation in 
neuronal somas and axons. Since existing BH3-profiling studies using adherent cells 
have been conducted mostly in cancer cells and immortalized cell lines, we performed 
initial experiments to determine the feasibility of this technique for use in primary 
neurons. While the injection experiments described above validated the ability of BH3 
peptides to promote cyt c release in primary sympathetic neurons, the key requirement 
for performing BH3-profiling on adherent cells is the ability to selectively permeablize 
the cell membrane while leaving the outer mitochondrial membrane intact.  
 To determine the feasibility of this approach in sympathetic neurons, we 
incubated 5 DIV neurons with increasing concentrations of digitonin for 15 or 60 
minutes. Initial digitonin concentrations were determined using existing literature as 
guidelines (Ryan and Letai, 2014). As a reporter for membrane permeablization, we 
employed the DNA intercalating agent Propidium Iodide (PI). PI is unable to cross the 
membrane of healthy, unpermablized cells, but intercalates into DNA and fluoresces 
upon entering the cell, allowing cellular membrane permeability to be assessed by the 
presence or absence of nuclear PI staining in live cells. After the initial assessment of 
cellular membrane permeability, the integrity of the mitochondrial membrane was 
assessed by fixing the cells and evaluating the status of cyt c in the cells by 
immunofluorescence, using Tom20 staining as a mitochondrial marker. The goal of this 
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experiment was to find a concentration of digitonin that permeablized the cell 
membrane, resulting in PI-positive nuclei, but did not permeablize the mitochondrial 
membrane, as determined by the presence of mitochondrial cyt c. As a positive control 
for cellular permeablization, cells were incubated with a high concentration of the 
detergent Triton-X-100, which would be expected to completely permeablize both cell 
and mitochondrial membranes.  
 We find that incubation of digitonin at concentrations of less than .005% is 
insufficient to permeablize the cell membrane of sympathetic neurons, even when cells 
are incubated for up to 60 minutes. .005% digitonin is insufficient to permeablize the cell 
membrane after 15 minutes, but succeeds in permablizing the membrane after 60 
minutes (Figure 3.7A). Immunofluorescence revealed that in these cells treated with 
.005% digitonin for 60 minutes, cyt c was maintained at the mitochondria, indicating that 
the mitochondrial membrane had not been permeablized. As expected, incubation with 
Triton-X-100 resulted in complete permeablization of both cellular and mitochondrial 
membranes within 15 minutes, resulting in PI-positive neurons with no detectable cyt c 
at their mitochondria (Figure 3.7B). Taken together, these results demonstrate the 
feasibility of digitonin permeablization as a means to study sympathetic neuron 
apoptosis. 
 In order to build on the promising preliminary results obtained thus far, I propose 
the following experiments: 
1) Combinatorial studies utilizing single-cell injection of BH3 peptides in varying 
combinations to determine their relative ability to induce cyt c release in young 
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neurons. It will be interesting to determine if the injection of BMF-BH3, which is 
known to act only as a sensitizer, is sufficient to promote the release of cyt c in 
neurons, or if it requires the presence of activator BH3-peptides as well. The 
ability of BMF-BH3 to accelerate cyt c release in response to NGF deprivation 
would serve as a useful control for ensuring that the peptide is biologically active. 
It has also been reported that the transmembrane domain of Puma is important 
for its ability to bind Bax, resulting in purified Puma-BH3 acting more like a 
sensitizer while full-length Puma can act as an activator. The results of 
experiments expressing all four BH3 genes (Bim, Puma, BMF, and HRK) would 
likely be difficult to interpret, as there is no way to determine if a given 
microinjected neuron is expressing all four plasmids to the same level, or indeed 
if one or more plasmids is not being expressed at all. However, the 
overexpression of individual full-length BH3 genes by plasmid microinjection 
should be more straightforward and would serve as a useful complement to BH3 
peptide injections. Different results between peptide injections and plasmid 
based overexpression studies could provide useful insight into the relative 
importance of the different domains of BH3 proteins in neuronal apoptosis.  
 
2) Further experiments to determine the mechanistic reasons for the differences 
observed in cyt c release in young and mature neurons in response to BH3-
peptide injections. BH3-peptide injection bypasses the known brakes on cyt c 
release engaged in mature neurons; namely the miRNAs miR-29 and miR-24. 
Thus, at least one additional brake likely exists at the level of Bax activation or 
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integration into the mitochondrial membrane. Bax activation could be inhibited in 
mature neurons by post-translational modification or interaction with a binding 
partner. There is precedence in the literature for both of these events; Bax can 
be phosphorylated by AKT at Serine 184, which inhibits its activation (Gardai et 
al., 2004). Bax activity can also be inhibited by protein binding partners (Su, 
Wang et al. 2006; Garner, Reyna et al. 2016). Given the range of known ways 
that Bax activation can be inhibited, as well as the potential for novel regulatory 
mechanisms, this is perhaps best examined by mass-spectrometric comparison 
of Bax immunoprecipitated from young and mature neurons.  
 
3) Following further optimization of the cellular permeablization protocol, BH3-
profling experiments on adherent sympathetic neurons can be carried out. 
Permeablization of a large population of cells would allow evaluation of cyt c 
release in response to BH3 peptide stimulation by both immunofluorescence and 
western blot, providing an advantage over single-cell microinjection experiments. 
More importantly, these experiments provide the opportunity to examine 
differences in cyt c release induced by these peptides in different cellular 
compartments, namely somas and axons. The effects of varying combinations of 
BH3 peptides can be evaluated by assaying the release of cyt c by 
immunofluorescence and/or western blot in young and mature neurons. 
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3.4: Figures and Figure Legends 
Figure 3.1: Indirect vs Direct Activation Models for Bax Activation 
In the direct activation model for Bax activation (A), direct activator BH3 proteins, such 
as Bim, are bound and inhibited by the anti-apoptotic members of the BCL-2 family, 
such as BCL-2 or BCL-xl. Sensitizer BH3 proteins, such as Bad, sequester the anti-
apoptotic BCL-2 family proteins, freeing the activator BH3 proteins to bind and activate 
Bax. In the indirect activation model (B), Bax is constitutively active to some degree, 
and is held in check by the anti-apoptotic BCL-2 family members. In this model, 
inhibition of this interaction between anti-apoptotic BCL-2 family members by BH3-only 
family members is sufficient to promote Bax activation and cell death. The unified model 
(C) proposes that both direct and indirect activation can occur, depending on cellular 
context and relative protein levels of each family member.   
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Figure 3.1 
 
Adapted from Czabotar et al., 2014 
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Figure 3.2: Treatment of Young Sympathetic Neurons with ABT-737 Induces Axon 
Degeneration 
Neurons isolated from neonatal mice were cultured for 5 days and then either 
maintained in NGF (A, B), treated with ABT-737 (C, D) or deprived of NGF (E, F). 
Images of somas and axons were captured from the same plate. ABT-737 treated 
neurons exhibit beaded axons similar to NGF-deprived neurons, but maintain phase 
bright somas similar to NGF-maintained neurons.  
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Figure 3.2 
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Figure 3.3: Differing Effects of ABT-737 on cyt c Release in Young and Mature 
Neurons 
Neurons isolated from neonatal mice and cultured for either 5 days (P5) or 28 days 
(P28), subjected to treatment with ABT-737 for 48 hours, then fixed and stained for cyt c 
or the mitochondrial marker Tom20. A) Treatment of young neurons with ABT-737 leads 
to widespread cyt c release in both somas and axons. B) Treatment of mature neurons 
with ABT-737 leads to cyt c release mainly in the axons, while somas largely maintain 
cyt c at the mitochondria. C) Mature neurons subjected to NGF deprivation for 24 hours 
prior to ABT treatment release cyt c release cyt c in both axons and somas, similar to 
young neurons. D) Quantification of the percentage of cells with mitochondrial 
(maintained) cyt c in each of the indicated condition. Data presented as mean ± SEM of 
at least 2 independent experiments. E) Western blot of cyt c levels in neurons subjected 
to the indicated treatments. Loss of cyt c expression or staining reflects degradation of 
cyt c after its release from the mitochondria. F) Percentage of cells displaying  
mitochondrial cyt c in mature neurons deprived of NGF in the presence or absence of 
Actin D or CHX for 24 hours prior to treatment with ABT-737, compared with NGF 
deprived neurons and NGF maintained, vehicle treated neurons, presented as mean 
±SEM from two independent experiments. 
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Figure 3.4: ABT-737 Upregulates Bim Expression in Sympathetic Neurons 
A) Quantification of neurons exhibiting mitochondrial cyt c in sympathetic neurons 
treated with ABT-737 in the presence or absence of CHX for 48 hours. –NGF +CHX 
condition is shown as a control for CHX efficacy. B) Western blot analysis of young (P5) 
and mature (P28) sympathetic neuron lysates probed with anti-Bim antibody. Tubulin is 
present as a loading control. C) Axon morphology of P5 neurons treated with vehicle,  
ABT-737 or ABT-737 +CHX for 72 hours. 
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Figure 3.4 
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Figure 3.5 Direct Injection of BH3-only Domain Peptides Is Sufficient to Cause 
Cytochrome c Release in Young, but not Mature SCGs 
A) Representative images of Neurons injected with a pooled combination of peptides 
comprising the purified BH3-domains of Bim, BMF, and Puma (BBP) or vehicle control 
(DMSO) were fixed and stained with anti-cytochrome c antibody. Injected cells are 
marked with FITC-Dextran. B) Quantification of the number of injected cells with 
mitochondrial cyt c, displayed as mean ± SEM of 3 independent experiments.  
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Figure 3.5 
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Figure 3.6 Optimization of Digitonin Concentration for Permeablizing Adherent 
Sympathetic Neurons 
A) Representative images of neuron cultures permeablized with digitonin. DMSO 
indicates vehicle control. Percentages represent digitonin concentration. PI staining is 
used as an indicator of cell membrane permeablization. B) Immunofluorescence 
staining of neurons incubated with the optimum concentration of digitonin (.005%) as 
determined in (A). Neurons were stained with anti-cyt c antibody as a readout for 
mitochondrial membrane permeablization and Tom20 as a mitochondrial marker. Triton 
X-100 was used as a positive control for mitochondrial membrane permeablization.   
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Figure 3.6 
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CHAPTER 4: DISCUSSION 
4.1: Summary of Findings 
 Creating a properly wired nervous system in which the appropriate neurons 
match up with the correct targets in the correct numbers is an intricately regulated 
process that requires a combination of neuronal differentiation, migration, axon 
outgrowth, and regulated degeneration, or apoptosis. Apoptosis serves a key role in 
development by allowing for the controlled removal of neurons that fail to 
differentiate, migrate, or innervate their targets properly. During the early stages of 
development, neurons voluntarily initiate their own destruction in a well regulated, 
orderly manner that depends on new protein synthesis. However, after the formation 
of the nervous system, the apoptotic pathway becomes restricted in neurons, likely 
to prevent aberrant activation of the apoptotic pathway which would be deleterious 
as neurons, with few exceptions, are not easily replaced if lost. This work provides 
important insight into the molecular mechanisms utilized by neurons to restrict the 
apoptotic pathway as they mature. 
 While it is clear that mature neurons restrict the apoptotic pathway by multiple 
redundant mechanisms, recent findings in the fields of axon pruning and synaptic 
plasticity have revealed that regulation of the apoptotic pathway can be controlled 
with far greater spatial precision than previously appreciated, even in mature 
neurons that have restricted the apoptotic pathway. This precise spatial regulation 
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allows neurons to engage the apoptotic pathway in a limited fashion in dendrites or 
axons to permit the controlled destruction of processes or even individual synaptic 
sites, such as dendritic spines, to facilitate nervous system plasticity. Here, we have 
investigated both the temporal regulation of the apoptotic pathway in developing 
neurons, and the spatial regulation of the apoptotic pathway that differs between 
somas and axons.  
Mature Neurons Dynamically Regulate Apoptosis Via Redundant Pre-Mitochondrial 
Brakes  
1) Sympathetic neurons acquire resistance to apoptosis by activating pre and post-
mitochondrial apoptotic brakes as early as 10-15 days in culture. 
2) Knockout of all three miR-29 family members in maturing sympathetic neurons 
fails to resensitize these neurons to apoptosis in response to NGF deprivation, 
indicating the presence of other brakes on the apoptotic pathway upstream of cyt 
c release. 
3) Other miRNAs with predicted targets in the apoptotic pathway, miR-24, miR-124, 
and miR-128, are upregulated in maturing neurons. 
4) Overexpression of miR-29 or miR-24, but not miR-124 or miR-128, is sufficient to 
inhibit cyt c release in response to NGF deprivation in sympathetic neurons. 
5) miR-29 and miR-24 can repress the induction of endogenous Bim  in sympathetic 
neurons. 
6) miR-24 can target the Puma 3’ UTR and inhibit DNA-damage-induced apoptosis 
in sympathetic neurons. 
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7) Inhibition of miR-24 activity in miR-29 deficient neurons does not completely 
resensitize mature neurons to apoptosis, possibly due to the presence of an 
additional brake on the apoptotic pathway at the level of c-jun phosphorylation. 
Spatial and Temporal Regulation of Bax Activation in Neurons 
1) ABT-737 treatment induces degeneration of axons, but not somas, in young 
sympathetic neurons.   
2) ABT-737 induces cyt c release in both somas and axons of young sympathetic 
neurons, but only in axons of mature sympathetic neurons. 
3) Pre-treatment with NGF-deprivation sensitizes mature neurons to ABT-737 
induced cyt C release in a protein-synthesis-independent manner.  
4) Treatment with ABT-737 unexpectedly leads to the accumulation of Bim in 
young, but not mature sympathetic neurons.  
5) Inhibition of protein synthesis at the time of CHX treatment in young neurons 
inhibits the cyt c release induced by ABT-737 treatment in neuronal somas, but 
axons still appear to degenerate. 
6) Cytosolic injection of BH3-only domain peptides is sufficient to induce cyt c 
release in young sympathetic neurons, but mature neurons are markedly more 
resistant. 
7) Partial permeablization of adherent sympathetic neurons with digitonin appears 
to be a feasible model for investigating the regulation of Bax activation by BH3-
only domain peptides.  
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4.2: Clinical Relevance 
Overexpression of miRNAs for Therapeutic Purposes 
 As discussed in the introduction, a number of miRNAs are dysregulated in cases 
of neurodegenerative disease. Additionally, overexpression of miR-29 has been found 
to be neuroprotective in in vivo models of stroke and spinal cord injury (Wang et al., 
2015; Khanna et al., 2013; Ouyang et al., 2013; Liu et al., 2015). miR-29 has also been 
found to target Beta-Amyloid Cleaving Enzyme (BACE1), which is an enzyme that 
cleaves Amyloid Precursor Protein (APP) to produce toxic Amyloid-β proteins in 
Alzheimer’s Disease (Hebert, Horre et al. 2008; Roshan, Ghosh et al. 2012; Lei, Lei et 
al. 2015). These findings, coupled with our own findings that miR-29 and miR-24 
overexpression can restrict the apoptotic pathway, suggest that overexpression of pro-
survival miRNAs such as miR-29 and/or miR-24 could have therapeutic potential for 
human pathologies.  
 Development of miRNAs as therapeutic entities is still in the early stages. The 
ability of miRNAs to simultaneously regulate multiple molecular pathways makes them 
attractive from a therapeutic perspective for disorders like cancer and 
neurodegeneration, where multiple pathways are known to be perturbed. Therapeutic 
strategies being pursued in clinical trials include both interfering with miRNA activity, as 
in the case of miR-122 and Hepatitis C Virus (Janssen, Reesink et al. 2013), and in 
replacing/overexpressing miRNAs, as with miR-34a and cancer (Mirna Therapeutics 
Clinical Trial NCT01829971).  
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 Treatment of diseases by miRNA overexpression or replacement has two chief 
obstacles to overcome: first, RNA degradation machinery, such as Ribonucleases, in 
the mammalian bloodstream can inhibit the stability of the miRNA duplex, preventing it 
from reaching its target tissue. Second, miRNAs do not readily cross cellular 
membranes, and miRNAs can only have a therapeutic effect from inside the cell. A 
number of different approaches are currently being explored to overcome these 
obstacles.  
 To enhance miRNA stability in the body, miRNA duplex mimics can be 
chemically modified; the addition of 2’F can protect against exonuclease activity, while 
conjugation to a molecule like cholesterol can enhance cellular uptake. Additional 
chemical modifications can be made to the sense strand of the miRNA duplex to 
prevent RISC loading and stop the sense strand from acting as an antimiR, which would 
diminish therapeutic efficacy. miRNA duplexes can also be loaded into liposome 
nanoparticles to aid their in vivo delivery. Indeed, the first miRNA restoration study to 
enter clinical trials makes use of liposomal nanoparticles to facilitate miRNA mimic 
delivery. miRNAs are also good candidates for gene-therapy mediated overexpression 
using lentiviral or adenoviral vectors (Zhang, Wang et al. 2013; Chen, Gao et al. 2015).  
 Delivery of miR-29 or miR-24 to the brain poses additional challenges compared 
to delivery of miRNAs to other tissues or tumors. Any treatment targeting the brain must 
cross the blood-brain barrier to achieve its effects. Animal studies have used direct 
injection of mimics into the brain as a straightforward means of overcoming this barrier, 
but this approach has obvious drawbacks for therapeutic use in humans. An approach 
that has been successfully used to deliver siRNAs and LNAs to the brain is the 
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conjugation of the RNA to a neurotropic peptide derived from the Rabies virus, known 
as RVG, which leads to neuronal uptake of RNAs (Kumar et al., 2007; Roshan et al., 
2014). This approach has allowed the brain-specific knockdown of target genes through 
systemic injection of the siRNA/RVG complex. This approach has also recently been 
adapted to work with miRNA mimics (Kumar, Wu et al. 2007; Hwang, Son et al. 2011).  
 Targeted delivery of miR-29 mimics in particular is important because 
overexpression of miR-29 in many mitotic cells has been found to induce apoptosis and 
cellular senescence, in contrast to its survival-promoting effects found in neurons (Mott 
et al., 2007; Martinez et al., 2011; Hu et al., 2014). Interestingly, a recent study from the 
pharmaceutical company Miragen explored the use of miR-29 mimics for the treatment 
of pulmonary fibrosis. miR-29 is known to target multiple extracellular matrix 
components, and it is thought that overexpression of miR-29 can inhibit the formation of 
fibrotic tissue and scars (He, Huang et al. 2013). In the Miragen preclinical study, a miR-
29 mimetic molecule with modifications to promote its stability and cellular uptake was 
able to inhibit disease progression in a mouse model of pulmonary fibrosis 
(Montgomery, Yu et al. 2014). Another group has also recently reported the successful 
delivery of a recombinant pre-miR-29 mimic into N2a695 cells, resulting in the 
downregulation of BACE1 expression and amyloid-beta protein levels (Pereira, Tomas 
et al. 2016).  
 It remains to be seen how well miR-29, miR-24, or indeed miRNAs in general, 
will ultimately work astherapeutic agents. Treating neurological diseases with miRNA 
will likely require further advances in enhancing miRNA delivery and efficacy. However, 
early clinical results manipulating other miRNAs appear promising (Janssen et al., 
132 
 
2013), and preclinical data from our lab and others certainly makes the case that miR-
29 and miR-24 merit further investigation as a therapeutic, both because of their ability 
to inhibit apoptosis as well as the ability of miR-29 in particular to target disease specific 
proteins such as BACE1 in Alzheimer’s Disease.  
 
Cell Death in Neurodegeneration 
 The work presented here invites an obvious question: if mature neurons are 
more resistant to cell death, how do neurons die in cases of neurodegeneration, which 
predominantly affect older individuals whose neurons should be mature? A definitive 
answer to this question is not yet known, and likely varies from one disease to another. 
There is evidence that some apoptotic brakes, such as miR-29 induction, are partially 
reversed in some neurodegenerative disorders, such as Alzheimer’s Disease or 
Huntington’s Disease (Hebert et al., 2008; Shioya et al., 2010). However, as discussed 
in the introduction, inhibition of apoptosis has not proved to be a “magic bullet” for 
stopping neurodegenerative disease. Indeed, evidence for the involvement of apoptosis 
in neurodegenerative disease has been controversial at best. The most noteworthy 
success for inhibiting a neurodegenerative disorder is likely the finding that Bax/Bak 
double deficiency delays cell death and disease progression in a mouse model of ALS 
(Reyes et al., 2010). However, even in this case, complete inhibition of the 
mitochondrial apoptotic pathway only had a modest effect on disease progression, 
neuronal survival, and animal lifespan, suggesting that neurons in ALS that would 
normally die of apoptosis die by other means when the apoptotic pathway is blocked.  
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  When surveying the literature on neurodegeneration and developmental 
apoptosis, one feature that is common to both is the activation of the cell cycle 
machinery in neurons. Apoptosis in young neurons is well established as requiring 
activation of cell-cycle proteins (Freeman et al., 1994). Inhibition of cell-cycle 
progression by pharmacological or genetic means protects neurons from apoptosis. 
Interestingly, aberrant activation of cell cycle machinery is also known to occur in the 
brains of Alzheimer’s Disease patients, as determined by the presence of elevated cell-
cycle related proteins and even multinucleate neurons in AD patient samples. This 
aberrant cell cycle reentery is thought to be a cause, rather than a consequence, of 
neurodegeneration (Vincent, Pae et al. 2003; Currais, Hortobagyi et al. 2009; Bonda, 
Lee et al. 2010). Enforced activation of the cell cycle in the brain by overexpression of 
Simian-Virus-40 (SV40) Large T Antigen has been found to induce neurodegeneration 
in mice, and this neurodegeneration exhibits two hallmarks of Alzheimer’s Disease: 
neurofibrillary tangles and Amyloid-β deposits (Park, Hallows et al. 2007).  Induction of 
neuronal cell-cycle reentry by overexpression of c-myc in forebrain neurons also leads 
to neurodegeneration and cognitive decline (Lee, Casadesus et al. 2009). 
 A limitation of many studies of neuronal cell death is that they make use of 
young, often embryonically derived cultured neurons. Stimulation of apoptosis in these 
neurons leads to cell-cycle reentry and relatively rapid death. However, in mature 
neurons where the apoptotic pathway is arrested, as described in this dissertation, 
sustained exposure to an apoptotic or pathological stimulus that lead to apoptosis in 
young neurons could lead to the partial induction of the apoptotic pathway in mature 
neurons, resulting in cell-cycle reentry without progressing to the point of caspase 
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activation and cell death. This theory is consistent with the “two-hit” hypothesis of 
Alzheimer’s Disease, which posits that neuron death in Alzheimer’s is a consequence of 
a combination of aberrant cell-cycle reentry and oxidative stress. Aberrant cell-cycle 
reentry is thought to place neurons in a weakened state, which renders them more 
vulnerable to a second “hit”, which this hypothesis proposes to be oxidative stress (Zhu, 
Lee et al. 2007)(Zhu et al., 2007). This second hit overwhelms the already stressed 
neurons, ultimately leading to the death of the cells. Interestingly, aberrant cell-cycle 
activation is not limited to Alzheimer’s Disease, and has also been observed in human 
cases and animal models of ALS and Huntington’s Disease (Ranganathan and Bowser 
2003; Pelegri, Duran-Vilaregut et al. 2008). It is unclear at this point whether this cell-
cycle reentry does in fact represent the aborted activation of the apoptotic pathway, or 
indeed what the precise stimulus is that causes cell-cycle reentry at all; however the fact 
that many of the toxic protein species found in the mature brain during 
neurodegenerative disorders are capable of inducing apoptosis in young neurons 
suggests that further investigation is warranted in this area.  
 
4.3: Non-Apoptotic Roles for Apoptotic Proteins 
 Another question raised by our findings that neurons become more resistant to 
apoptosis with maturation is: why would neurons continue expressing any apoptotic 
proteins at all? If the goal is to shut down the pathway, why not shut the pathway all the 
way down? The likely answer to this is that apoptotic proteins have jobs in the cell 
independent of their role in apoptosis. Indeed, a large number of recent studies have 
demonstrated that apoptotic pathway genes have roles outside of their “day jobs” as the 
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executioners of the cell death pathway. While the classic example of this phenomenon 
is cytochrome c, which was well established as an electron-transport-chain component 
prior to its key role in the apoptotic pathway being identified, recent evidence 
demonstrates non-apoptotic roles for other members of the apoptotic pathway as well.  
Bax and Caspases in Synaptic Plasticity and Synapse Remodeling 
 The first major finding indicating that the apoptotic pathway might be involved in 
synaptic plasticity in the mammalian brain was made in the lab of Dr. Morgan Sheng in 
2010 (Li et al., 2010). Their study found that in hippocampal neurons, stimulation of 
NMDA receptors can lead to a low level of Caspase 3 activation, and that Caspase 
activity was required for the onset of Long-Term Depression (LTD) in these neurons by 
a mechanism that involves the regulation of AMPA receptor trafficking. LTD could be 
prevented by pharmacological caspase inhibitors, overexpression of the endogenous 
caspase inhibitor XIAP, or genetic knockout of Caspase 3. Interestingly, they also noted 
that overexpression of BCL-XL, which acts upstream of Caspases, could also inhibit 
LTD, suggesting the involvement of Bax. Sure enough, a paper published the very next 
year (Jiao and Li 2011) reported the finding that Bax and the BH3-only protein Bad are 
also required for the development of NMDAR-Dependent LTD in hippocampal neurons. 
Interestingly, this paper was unable to detect increased active Bax in the mitochondrial 
fraction obtained from NMDA-stimulated cells by immunoprecipitation. This raises the 
possibility that Bax could activate Caspase 3 in a manner that does not involve 
mitochondria under these circumstances, but it could also be that Bax permeablizes 
only a small number of mitochondria, or does so in a limited fashion in these cells that is 
difficult to detect by Western blotting on mass cultures. Indeed, so-called “minority 
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MOMP”, where a limited population of mitochondria in within a given cell are 
permeablized, has recently been described in cancer cells (Ichim, Lopez et al. 2015).  
 Another mechanism through which limited Caspase activation is believed to 
regulate nervous system plasticity is through the elimination of synapses themselves. 
Synaptic spine density has been found to be increased in the brains of Caspase 3 
knockout mice, and local activation of Caspase 3 by optogenetic means has been found 
to result in the loss of synaptic spines in cultured hippocampal neurons (Ertürk, Wang et 
al. 2014). Caspase 3 was also found to regulate post-synaptic structures at the 
neuromuscular junction by cleavage of the protein Dishevelled (Wang, Chen et al. 
2014). The cell death pathway was also found to regulate synapse elimination in the 
nematode worm C. elegans (Meng, Mulcahy et al. 2015).  
 Sublethal activation of caspases has also been implicated in other neuronal 
processes, such as axon pathfinding (Unsain and Barker, 2015). The chemotrophic 
response of neuronal axons in the retina to netrin or lysophosphatidic acid has been 
found to depend on the activity of caspase 3 and 9 (Campbell and Holt 2003; Campbell 
and Okamoto 2013). In olfactory neurons, Caspase-9 and Apaf-1 knockout animals 
were found to display defects in axon projection and synapse formation (Ohsawa, 
Hamada et al. 2010). Inhibition of Caspase 3 activity has also been found to cause 
defects in the regeneration of injured neurons in the mouse Dorsal Root Ganglia (DRG) 
and in injured sensory and motor axons in C. elegans (Verma, Chierzi et al. 2005; 
Pinan-Lucarre, Gabel et al. 2012; Ozturk, Cengiz et al. 2013).  
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 Neuronal plasticity is important for learning and memory as organisms adapt to 
new environments. Combined with the results from our lab and others that demonstrate 
inhibition of the apoptotic pathway in mature neurons, these findings suggest that 
neurons possess a previously unappreciated ability to precisely control both the level 
and location of the activation of the apoptotic pathway. The precise mechanisms 
through which cells achieve this measure of control are still being studied, but it is likely 
that the increasing restriction of the apoptotic pathway in mature neurons that we have 
described helps prevent limited activation of apoptosis for the purposes of synaptic 
plasticity from compromising the survival of the cell. 
 A more complete understanding of how local or low-level activation of the 
apoptotic machinery is regulated is crucial, as there is accumulating evidence that 
aberrant caspase activation in different subcellular compartments may play a role in 
neurodegeneration. In Huntington’s Disease, the toxic protein Huntingtin is known to be 
a Caspase substrate, and its cleavage by Caspases may play a role in Huntingtin 
clearance from the brain (Gafni, Papanikolaou et al. 2012). In Alzheimer’s Disease, 
patients are known to exhibit decreases in synaptic density and changes in synaptic 
function (Ferrer and Gullotta 1990; Ingelsson, Fukumoto et al. 2004). Animal models 
investigating the effects of Aβ overexpression have found similar defects in synaptic 
function, and these defects have been found to be caspase dependent (Kim, Anwyl et 
al. 2001; Shankar, Li et al. 2008; D'Amelio, Cavallucci et al. 2011). 
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Concluding Remarks 
 The results described here provide important insights into how neurons restrict 
the apoptotic pathway during development at the level of miRNAs and byond. They 
highlight how upregulation of certain miRNAs can make neurons more resistant to 
stressful stimuli like trophic factor deprivation or DNA damage, which could have 
therapeutic implications in neurological diseases. Interesting future directions to explore 
include optimizing neuronal delivery of miRNAs to the brain in vivo for the treatment of 
neurological disorders, as well as further mechanistic exploration of how certain 
neurons in the adult brain are able to engage the apoptotic pathway in a limited fashion 
to help facilitate neuronal plasticity.  
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